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Welcome
Welcome to the 6th Biennial Heart Valve Biology and Tissue
Engineering Meeting, which promises to be a stimulating and
informative meeting with a truly international faculty and audience.
The field of heart valve biology and tissue engineering a heart valve
continue to expand. The presentations at this meeting reflect the
advances made in both areas due to the multi-disciplinary approach
taken by many laboratories.
This meeting provides a forum that fosters an environment in which
these advances can be reported and discussed. There are also a
number of keynote lectures at the start of each session, providing a
state-of-the-art perspective for each session. Lastly, Wednesday
evening entails a fully moderated poster session and a prize for the
best poster.
On Thursday evening you are invited to join us on the boat cruise
along the river Thames, through the heart of London, where you will
be able to enjoy excellent views of many of the London landmarks
as well as some good food and excellent company.
We hope you enjoy the meeting and the wonderful facilities offered
by the Royal Society in this historic and inspiring environment!

Magdi Yacoub

Ajit Yoganathan

Adrian Chester
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Programme at a Glance
Wednesday 10th September
8.15‐8.30
8.30‐10.30

Welcome Address – Magdi Yacoub
Session 1 – Heart Valve Development and Function
Chairs: Giovanni Ferrari & Jonathan Butcher
Keynote Lecture: Katherine Yutzy (Cincinnati Children’s Hospital)

11.00‐13.00

Session 2 – Major players in valve function in health and disease I
Chairs: Adrian Chester & Murali Padala
Keynote Lecture: Jane Grande‐Allen (Rice University)

14.00‐16.00

Session 3 – Major players in valve function in health and disease II
Chairs: Magdi Yacoub & Colin Caro
Keynote Lecture: Peter Davies (University of Pennsylvania)

16.30‐18.00

Session 4 ‐ Mechanobiology
Chairs: Ajit Yoganathan & Craig Simmons
Keynote Lecture: Remi Peyronnet (Imperial College London)

18.00‐20.00

Session 5 – Posters and Welcome Reception
Assessors: Michael Sacks, Frank Baaijens, Ulrich Stock & Dan Simonescu

Thursday 11th September
308.30‐10.30

Session 6 – Intelligent Scaffolds
Chairs: Jerome Sohier & Ibrahim
Keynote Lecture: Karen Wooley (Texas AM University)

14.00‐16.00

Session 8 – Immuntolerance for tissue engineering applications
Chairs: Jane Grande‐Allen & Herman Waldman
Keynote Lecture: Kathy Liu (Harvard University)

16.30‐18.00

Session 9 – Gene Expression & Biomarkers in Valve Disease
Chairs: Elena Aikawa & Najma Latif
Keynote Lecture: Dennis Cokkinos (Academy of Athens)

Friday 12th September
8.30‐10.30
8.30‐9.00

Session 10 – The Ross Procedure
Chairs: Jane Sommerville & Giovanni Battista Luciani
Keynote Lecture: Ismail El‐Hamamsy (Montreal Heart Institute)

11.00‐13.00
11.00‐11.30

Session 11 – Valve Conserving Operations ‐ From Structure to Function
Chairs: Axel Haverich & Magdi Yacoub
Keynote Lecture: Martin Misfeld (Liepzig)

13.30‐13.30

Session 12 – Taking Cardiac Surgery to the People
Chair Jane
Sommerville
Keynote Speaker: Magdi Yacoub (Imperial College London)
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The Royal Society
The Royal Society, is a learned society for science, and is possibly the oldest such
society still in existence. Founded in November 1660, it was granted a Royal Charter
by King Charles II as the "Royal Society of London". The Society today acts as a
scientific advisor to the British government, receiving a parliamentary grant-in-aid.
The Society acts as the UK's Academy of Sciences, and funds research fellowships
and scientific start-up companies.
The Royal Society started from groups of physicians and natural philosophers,
meeting at variety of locations, including Gresham College in London. They were
influenced by the "new science", as promoted by Francis Bacon in his New Atlantis,
from approximately 1645 onwards. A group known as The Philosophical Society of
Oxford was run under a set of rules still retained by the Bodleian Library.
After the English Restoration, there were regular meetings at Gresham College. It is
widely held that these groups were the inspiration for the foundation of the Royal
Society.
The Society has a variety of functions and activities. It supports modern science; it
finances approximately 700 research fellowships for both early and late career
scientists, along with innovation, mobility and research capacity grants. Its Awards,
prize lectures, and medals all come with prize money intended to finance research,
and it provides subsidised communications and media skills courses for research
scientists. Through its Science Policy Centre, the Society acts as an advisor to the
European Commission and the United Nations on matters of science. It publishes
several reports a year, and serves as the Academy of Sciences of the United
Kingdom. Since the middle of the 18th century, government problems involving
science were irregularly referred to the Society, by 1800 it was performed
accordingly.
The premises in which we are now in are a Grade I listed building and the current
headquarters of the Royal Society. The first Carlton House was named after Baron
Carleton, and was sold to Lord Chesterfield in 1732, who held it on trust for
Frederick, Prince of Wales. Frederick held his court there until his death in 1751,
after which it was occupied by his widow until her death in 1772. In 1783, the thenPrince of Wales, George, bought the house, instructing his architect Henry Holland
to completely remodel it. When George became King, he authorised the demolition
of Carlton House, with the request that the replacement be a residential area. John
Nash eventually completed a design that saw Carlton House turned into two blocks
of houses, with a space in between them. The building is still owned by the Crown
Estates and leased by the Society; it underwent a major renovation from 2001 to
2004 at the cost of £9.8 million, and was re-opened by the Prince of Wales on 7th
July 2004.
The Society is governed by its Council, which is chaired by the Society's President,
according to a set of Statutes and Standing Orders. The members of Council and the
President are elected from, and by, its Fellows, the basic members of the Society,
who are themselves elected by existing Fellows. There are currently about 1,450
Fellows, allowed to use the post nominal title FRS (Fellow of the Royal Society), with
up to 52 new Fellows appointed each year. There are also Royal Fellows, Honorary
Fellows, and Foreign Members.
5

Conference Dinner
The conference dinner will be aboard the Pride on London riverboat. The boat will
depart from Westminster Pier (see map) within a 10 minute walk from the Royal
Society. The boat will depart at 19.45 and will return to Westminster at approximately
23.45. There will be a buffet style BBQ on the boat along with wine, beer and soft
drinks. The boat is covered, with an upper viewing deck.
Please dress appropriately for the weather conditions on the day of the cruise.

Royal Society

Westminster Pier
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Programme in Full
Wednesday 10th September
8.15‐8.30
8.30‐10.30
8.30‐9.00
9.00‐9.15

Welcome Address – Magdi Yacoub
Session 1 – Heart Valve Development and Function
Chairs: Giovanni Ferrari & Jonathan Butcher
Keynote Lecture: Katherine Yutzy (Cincinnati Children’s Hospital)
C1
Extracellular Matrix Composition Regulates Endothelial to Mesenchymal
Transformation
Sudip Dahal1, Jonathan Bramsen1, Peter Huang2, Gretchen Mahler1
1
Binghamton University, Department of Bioengineering, Binghamton, NY, USA,
2
Binghamton University, Department of Mechanical Engineering, Binghamton, NY,
USA

9.15‐9.30

C2

9.30‐9.45

C3

9.45‐10.00

C4

10.00‐10.15

C5

10.15‐10.30

C6

10.30‐11.00

Cyclic stretch orchestration of RhoA‐Rac1 signaling axis is essential for
embryonic valve remodeling
Russell Gould1, Huseyin Cagatay2, Joanna MacKay3, Sanjay Kumar3, Jonathan
Butcher1
1
Cornell University, Ithaca, NY, USA, 2Dogus University, Istanbul, Turkey, 3University
of California, Berkeley, Berkeley, CA, USA
Insights Into Regional Adaptations In The Growing Pulmonary Artery Using A
Meso‐scale Structural Model: Effects Of Ascending Aorta Impingement
Michael Sacks1, 1Institute of Computational Engineering and Sciences Department
of Biomedical Engineering University of Texas at Austin, Austin, USA
Modulation Of Human Valve Interstitial Cell Phenotype and Function Using A
FGF2 Formulation
Najma Latif1 ,2, Alfred Quillon1, Ann McCormack1, Alec Lozanoski1, Magdi Yacoub1
,2
, Adrian Chester1 ,2
1
Imperial College, London, UK, 2Qatar Cardiovascular Research Centre, Doha,
Qatar
Deletion of Krox20 results to bicuspid aortic valve
Gaelle Odelin1 ,,2, Emilie Faure1 ,2, Corinne Maurel‐Zaffran1 ,3, Fanny Coulpier4 ,5,
Piotr Topilko4 ,5, Patrick Charnay4 ,5, Stéphane Zaffran1 ,2
1
Aix Marseille Universite, Marseille, France, 2INSERM GMGF U910, Marseille,
France, 3CNRS, IBDML UMR7288, Marseille, France, 4INSERM U1024, IBENS, ENS,
Paris, France, 5CNRS, UMR8197, IBENS, ENS, Paris, France
Pharmacological Treatment in Marfan Mitral Valve: A Pilot Study
Alexander Black1, Vincent Griffiths1, Dalibor Soukup2, Jonathan McGuinnes3,
Darren McLoughlin3, John Byrne3, Mark Redmond3, Harry C. Dietz4, Peter Dockery1
1
Anatomy, School of Medicine, National University of Ireland, Galway, Galway,
Ireland, 2Institute for Science and Technology in Medicine, Keele University, Stoke‐
on‐Trent, UK, 3Department of Surgical Research, The Royal College of Surgeons in
Ireland, Dublin, Ireland, 4Department of Medical Genetics, Johns Hopkins
University Hospital, Baltimore, USA
Coffee break
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11.00‐13.00
11.00‐11.30
11.30‐11.45

11.45‐12.00

12.00‐12.15

12.15‐12.30

12.30‐12.45

12.45‐13.00

13.00‐14.00
14.00‐16.00
14.00‐14.30
14.30‐14.45

Session 2 – Major players in valve function in health and disease I
Chairs: Adrian Chester & Murali Padala
Keynote Lecture: Jane Grande‐Allen (Rice University)
C7
COX2 Inhibition Reduces Aortic Valve Calcification In Vivo
Elaine Wirrig, Robert Hinton, Katherine Yutzey
The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio,
USA
C8
Extracellular Adenine Nucleotide Catabolism on the Calcified Aortic Valve
Surface and its Clinical Correlates
Barbara Kutryb‐Zajac1, Patrycja Sommerfeld1, Marta Toczek1, Paulina Zukowska1,
Romuald Lango2, Jan Rogowski3, Ewa M. Slominska1, Ryszard T. Smolenski1
1
Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland,
2
Department of Cardiac Anesthesiology, Medical University of Gdansk, Gdansk,
Poland, 3Chair and Clinic of Cardiac and Vascular Surgery, Medical University of
Gdansk, Gdansk, Poland
C9
Characterisation of human cardiovascular tissue affected by calcific disease
using Raman and scanning electron microscopy
Amanda You1 ,2, Sergio Bertazzo1, Jean‐Philippe St‐Pierre1 ,2, Joseph Steele1 ,2,
Adrian Chester4, Magdi Yacoub4, Molly Stevens1 ,2
1
Department of Materials, Imperial College London, London, UK, 2Department of
Bioengineering, Imperial College London, London, UK, 3Institute of Biomedical
Engineering, Imperial College London, London, UK, 4National Heart and Lung
Institute, Imperial College London, London, UK
C10 Analysis of The Retinoblastoma Protein In pAVIC Calcification
Marina Freytsis1, Jenna Calvino3, Lauren Baugh5, Lauren Black5 ,1, Philip Hinds1 ,4,
Gordon Huggins2 ,3
1
Tufts University, Sackler School of Graduate Biomedical Research, Boston, MA,
USA, 2Tufts Medical Center, Boston, MA, USA, 3Molecular Cardiology Research
Institute, Boston, MA, USA, 4Molecular Oncology Research Institute, Boston, MA,
USA, 5Tufts University, Department of Biomedical Engineering, Medford, MA, USA
C11 Investigating The Role Of Matrix Vesicles In Valve Interstitial Cell Calcification
Lin Cui1, Dongxing Zhu1, Francesco Rao2, Colin Farquharson1, Vicky MacRae1
1
The Roslin Institute, Edinburgh, Midlothian, UK, 2Dundee Cell Products Ltd,
Dundee, UK
C12 eNOS Uncoupling Drives Calcification Via Disruption of Endothelial Protection In
Early And Late Stages 0f Aortic Valve Disease
Emily Farrar1, Geoffrey Huntley2, Jonathan Butcher1
1
Cornell University, Ithaca, NY, USA, 2Brown University, Providence, RI, USA
Lunch
Session 3 – Major players in valve function in health and disease II
Chairs: Magdi Yacoub & Colin Caro
Keynote Lecture: Peter Davies (University of Pennsylvania)
C13 Characterization of Sex‐Related Differences in Valvular Interstitial Cell Response
to Transforming Growth Factor‐beta1
Chloe McCoy, Ashley Quinn, Kelsey Duxstad, Kristyn Masters
University of Wisconsin, Madison, WI, USA
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14.45‐15.00

C14

15.00‐15.15

C15

15.15‐15.30

C16

15.30‐15.45

C17

15.45‐16.00

C18

16.00‐16.30
16.30‐18.00
16.30‐17.00
17.00‐17.15

17.15‐17.30

Insights into CAVD Pathobiology and Relationship to Atherosclerosis Provided
by Familial Hypercholesterolemic Swine
Ana Porras, Dhanansayan Shanmuganayagam, Jennifer Meudt, Christian Kreuger,
Jess Reed, Kristyn Masters
University of Wisconsin‐Madison, Madison, WI, USA
Deficiency Of C‐Type Natriuretic Peptide Signaling Promotes Aortic Stenosis, Left
Ventricular Dysfunction, And Bicuspid Aortic Valves In Mice
Mark Blaser1, Yu‐Qing Zhou2, Hangjun Zhang3, Scott Heximer3, Mark Henkelman2,
Craig Simmons1 ,4
1
Institute of Biomaterials and Biomedical Engineering, University of Toronto,
Toronto, Ontario, Canada, 2Mouse Imaging Centre, Toronto Centre for
Phenogenomics, Toronto, Ontario, Canada, 3Department of Physiology, University
of Toronto, Toronto, Ontario, Canada, 4Department of Mechanical and Industrial
Engineering, University of Toronto, Toronto, Ontario, Canada
Pharmacological Antagonist Of Serotonin Receptor 2A Reduces The Pathological
Activation of Human Mitral Valve Interstitial Cells: Implication For Myxomatous
Mitral Valve Disease
Kathryn Driesbaugh1, Erik Lai1, Emanuela Branchetti1, Juan B Grau1 ,2, Robert C
Gorman1, Joseph H Gorman1, Michael S Sacks4, Joseph E Bavaria1, Robert J Levy1 ,3,
Giovanni Ferrari1
1
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA,
2
The Valley Hospital, Ridgewood, NJ, USA, 3The Children's Hospital of Philadelphia,
Philadelphia, PA, USA, 4The University of Texas at Austin, Austin, TX, USA
Effect Of Mitral Regurgitation Severity And Extent Of Leaflet Tethering On
Leaflet Remodeling In Ischemic Mitral Regurgitation
Kanika Kalra, Robert Guyton, Vinod Thourani, Muralidhar Padala
Emory University, Atlanta, USA
Filmain–A Mutations Causing Mitral Prolapse Alter Integrin Expression and
Cellular Mechanotransduction
Muralidhar Padala1 ,2, Marzieh Zamani2 ,4, Padmini Sarathchandra2, Jean Merot3,
Julia Gorelik4, Magdi Yacoub2 ,4, Adrian Chester2 ,4
1
Emory University, Atlanta, GA, USA, 2Harefield Heart Science Centre, Harefield,
Middlesex, UK, 3University of Nantes, Nantes, France, 4Imperial College London,
London, UK
Coffee Break

Session 4 ‐ Mechanobiology
Chairs:Ajit Yoganathan & Craig Simmons
Keynote Lecture: Remi Peyronnet (Imperial College London)
C19 Paracrine TGF‐β Signaling Amplifies Mechanical Force‐Regulated Pulmonary
Valve Leaflet Gene Expression
Xiaoyuan Ma, Katsuhide Maeda, Seta Stanbouly, Yasuhiro Fujii, Frank Hanley, R.
Kirk Riemer
Stanford University, Stanford, CA, USA
C20 Role of Shear‐ and Side‐dependent MicroRNAs in Aortic Valve Biology
Swetha Rathan1, Anita Rajamani1, Shan Lee1, Sandeep Kumar2, Ann
Aphivantrakul1, Hanjoong Jo1 ,2, Ajit Yoganathan1 ,2
1
Georgia Institute of Technology, Atlanta, GA, USA, 2Emory University, Atlanta, GA,
USA
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17.30‐17.45

C21

17.45‐18.00

C22

18.00‐20.00

Session 5 – Posters and Welcome Reception
Assessors: Michael Sacks, Frank Baaijens, Ulrich Stock & Dan Simonescu
P1
Chondrogenic Pathways Involved In The Development of Myxomatous Valve
Disease
Alexia Hulin1, Jonathan Cheek1, Christina Alfieri1, Robert Hinton1, Alain Colige2,
Katherine Yutzey1
1
The Heart Institute, Cincinnati Children's Hospital, Cincinnati, Ohio, USA, 2GIGA,
Laboratory of Connective Tissues Biology, Sart‐Tilman, Belgium
P2
Versican Is Markedly Elevated During The Early Pathogenesis Of Murine Aortic
Valve Disease
Mark Blaser1, Jung‐Woo Kwon1, Kuiru Wei1, Yu‐Qing Zhou2, Mark Henkelman2,
Craig Simmons1 ,3
1
Institute of Biomaterials and Biomedical Engineering, University of Toronto,
Toronto, Ontario, Canada, 2Mouse Imaging Centre, Toronto Centre for
Phenogenomics, Toronto, Ontario, Canada, 3Department of Mechanical and
Industrial Engineering, University of Toronto, Toronto, Ontario, Canada
P3
Non‐Linear Optical Visualisation Technologies For Characterisation Of Aortic
Valve Sclerosis In A Murine Model
Anett Jannasch1, Saskia Faak1, Christian Schnabel2, Roberta Galli2, Edmund Koch2,
Klaus Matschke1, Thomas Waldow1
1
Department of Cardiac Surgery, Faculty of Medicine, TU Dresden, Herzzentrum
Dresden, Dresden, Germany, 2Institute of clinical Sensoring and Monitoring,
Faculty of Medicine, TU Dresden, Dresden, Germany
P4

P5

Influence of Aortic and Ventricular Shear Stresses on the stiffness of Valve
Endothelial Cells
Napachanok Mongkoldhumrongkul1, Jose Sanchez‐Alonso1, Padmini
Sarathchandra1, Julia Gorelik1, Magdi Yacoub1 ,2, Adrian Chester1 ,2
1
Imperial College London, London, UK, 2Qatar Cardiovascular Research Centre,
Doha, Qatar
Valve Interstitial Cell Remodeling Under Abnormal Mechanical Stress is
Mediated by 5HT and FGF2 Signaling
Ngoc Thien Lam1, John Carradini1, Atefeh Razavi1, Shree Sharma2, Kartik
Balachandran1
1
University of Arkansas, Fayetteville, AR, USA, 2University of Arkansas for Medical
Sciences, Little Rock, AR, USA

Patient‐Specific Fluid Structure Interaction Simulation of Ascending Thoracic
Aortic Aneurysm Using In Vivo Magnetic Resonance Imaging
Liang Ge1 ,2, Henrik Haraldsson1, David Saloner1 ,2, Michael Hope1 ,2, Elaine Tseng1 ,2
1
University of California San Francisco, CA, USA, 2San Francisco VA Medical Center,
San Francisco, CA, USA
Tissue‐Engineered Textile‐Reinforced Mitral Valve ‐ Second Generation TexMi
Ricardo Moreira1, Valentine N. Gesche2, Luis G. Hurtado‐Aguilar1, Nuno Alves1,
Thomas Schmitz‐Rode1, Julia Frese1, Stefan Jockenhoevel1,2, Petra
Mela1, 1Department of Tissue Engineering & Textile Implants, AME‐Hemholtz
Institute for Biomedical Engineering, RWTH Aachen, Aachen, Germany, 2Institut für
Textiltechnik, RWTH Aachen, Aachen, Germany
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P6

P7

P8

P9

P10

P11

P12

P13

P14

Novel CALP Pericardium Shows Superior Hydrodynamics and Fluid Structure
Interaction Compared to Current Bioprosthetic Valve Tissues: A Computer
Simulation
Yaghoub Dabiri1, Todd J Anderson1, John V Tyberg1, Janet Ronsky2, Imtiaz Ali1,
Michael Wong1, Kishan Narine1
1
University of Calgary Libin Cardiovascular Institute of Alberta, Calgary, Canada,
2
University of Calgary Schulich School of Engineering, Calgary, Canada
Characterization and Validation of a 3D PEG‐NB Screening Platform for
Improved MSC‐Based Heart Valve Tissue Engineering
Jenna Usprech1, Craig Simmons1 ,2
1
Institute of Biomaterials and Biomedical Engineering, Toronto, Ontario, Canada,
2
Mechanical and Industrial Engineering, Toronto, Ontario, Canada
Assessment of Parylene C Thin Films for Heart Valve Tissue Engineering
Isra Marei1 ,2, Adrian Chester1, Themistoklis Prodromakis3, Tatiana Trantidou3,
Magdi H. Yacoub1
1
Heart Science Centre, Harefield Hospital , National Heart and Lung Institute ,
Imperial College London, London, UK, 2Qatar Science Leadership Program, Qatar
Foundation, Doha, Qatar, 3Centre for Bio‐Inspired Technology, Institute of
Biomedical Engineering, Imperial College London, London, UK
Surface Functionalization Of Anisotropic Nanofibers For Driving Human
Mesenchymal Stem Cell Behaviour
Ivan Carubelli1, Jerome Sohier2, Ann McCormack1, Padmini Sarathchandra1, Adrian
Chester1, Magdi Yacoub1
1
Magdi Yacoub Institute, Harefield Heart Science Centre, Imperial College London,
Harefield, UK, 2Laboratory of Tissue Biology and Therapeutic Engineering (LBTI),
UMR 5305, CNRS, Lyon, France
PNGase F removes glycocalyx structures of decellularized porcine pulmonary
heart valve matrices
Katja Findeisen, Axel Haverich, Andres Hilfiker
MHH; LEBAO, Hannover, Germany
BMP‐pSmad1/5/8 Pathway Activation in a Novel Mouse Model of Calcific Aortic
Valve Disease
M. Vicky Gomez1 ,2, Jonathan D. Cheek1, Elaine E. Wirrig1, Katherine E. Yutzey1 ,2
1
Cincinnati Children's Hospital, Cincinnati, OH, USA, 2University of Cincinnati,
Cincinnati, OH, USA
Mild Hyperlipidemia Induces Aortic Valve Disease And An Osteoporotic
Phenotype In Aged Mice
Rachel Adams1, Mark Blaser1, Yu‐Qing Zhou2, Celeste Owen2, R. Mark Henkelman2,
Craig Simmons1
1
Institute of Biomaterials and Biomedical Engineering, University of Toronto,
Toronto, Ontario, Canada, 2Mouse Imagine Centre at the Toronto Centre for
Phenogenomics, Toronto, Ontario, Canada
Relationship Between Free Aldehyde Groups In Bioprosthetic Heart Valves And
Calcification
Tara Tod, Jeff Dove
Edwards Lifesciences, Irvine, Ca, USA
Investigating the Potential of Valve Interstitial Cells to Act in a Pericyte Manner
by Promoting Angiogenesis and Invasion by Valve Endothelial Cells
Christopher Arevalos, Kathryn Grande‐Allen
Rice University, Houston, TX, USA
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P15

P16

P17

P18

P19

P20

P21

P22

P23

P24
P25

MG53‐Mediated Protection in Heart Valve Biology
T.M. Ayodele Adesanya1, Hua Zhu1, Tao Tan1, Ki Ho Park1, Joy Lincoln2 ,1, Jianjie
Ma1
1
The Ohio State University, Columbus, Ohio, USA, 2Nationwide Children's Hospital,
Columbus, Ohio, USA
Relevance of YAP/TAZ Transcriptional Co‐factors on Mechanotransduction of
Aortic Valvular Interstitial Cells
Claudia Dittfeld, Wolfgang Witt, Anett Jannasch, Janin Andres, Maria Feilmeier,
Klaus Matschke, Thomas Waldow
Medical Faculty, TU Dresden, Dresden, Germany
An In Vitro Model for the Investigation of Potential Mechanical Interactions
Between Surgical Sealants and Aortic Tissue
Stacy Arnold1, David Gale1, David Hollinworth1, Davide Pacini2
1
CryoLife, Kennesaw, GA, USA, 2University of Bologna, Bologna, Italy
Optimization Of Cyclic Stretching For Acceleration Of Collagen Production In
Fibrin‐Based Engineered Tissue Equivalents
Robert Tranquillo, Jill Schmidt
Univ. of Minnesota, Minneapolis, MN, USA
Parameter Estimation of Heart Valve Leaflet Hyperelastic Mechanical Behavior
Using An Inverse Modeling Approach
Ankush Aggarwal1, Michael S. Sacks1, 1Center for Cardiovascular Simulation
Institute of Computational Engineering and Sciences Department of Biomedical
Engineering, Austin, USA
A Computational Framework for Multiscale Modeling of the Mitral Valve
Chung‐Hao Lee1, Michael S. Sacks1, 1Center for Cardiovascular Simulation Institute
of Computational Engineering and Sciences Department of Biomedical Engineering
University of Texas at Austin, Austin, USA
A novel experimental/numerical method to assess BHV biomaterial fatigue
response in‐vivo
Kristen R. Feaver1, Will Zhang1, Hobey Tam2, Jeremy R. McGarvey3, Norihiro
Kondo3, Robert C. Gorman3, Joseph H. Gorman3, Narendra Vyavahare2, Michael S.
Sacks1
1
University of Texas at Austin, Austin, USA, 2University of Clemson, Clemson, USA,
3
University of Pennsylvania, Philadelphia, USA
Adipose‐Derived Stem Cells as a Potential Source of Valve Endothelial Cells
Napachanok Mongkoldhumrongkul1, Magdi Yacoub1 ,2, Adrian Chester1 ,2
1
Imperial College London, London, UK, 2Qatar Cardiovascular Research Centre,
Doha, Qatar
A New Strategy for Heart Valve Decellularization for Tissue Engineering
Jessica Boldt, Georg Lutter, Beke Sarrahs, Jan Schoettler, Jochen Cremer, Anja
Metzner
University hospital Schleswig‐Holstein, Campus Kiel, Department of Cardiovascular
Surgery, Kiel, Germany
WITHDRAWN
Adipose Tissue‐Derived Stem Cell Sourcing for Heart Valve Tissue Regeneration;
Selection of the Optimal Anatomical Site and Harvesting Procedure in Sheep
Marius Harpa1, Terezia Preda1, Ionela Movileanu1, Ovidiu Cotoi1 ,2, Dan
Simionescu1 ,2
1
University of Medicine and Pharmacy, Tirgu Mures, Romania, 2Clemson
University, Clemson SC, USA
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P26

P27

P28

P29

P30

P31

Decellularisation of Allogeneic Aortic and Pulmonary Valves using Low
Concentration SDS
Tayyebeh Vafaee1, Daniel Thomas1, Paul Rooney2, John N Kearney2, Helen Berry3,
Louise Jennings1, John Fisher1, Eileen Ingham1
1
University of Leeds, Leeds, UK, 2NHS Blood and Transplant Tissue Services,
Liverpool, UK, 3Tissue Regenix Group plc, York, UK
Comparative Analysis of the Chemoattractive Properties of Human
Mesenchymal Stem Cells
Debora Kehl1, Benedikt Weber1, Marten Schneider2, Simon P. Hoerstrup1
1
Swiss Center for Regenerative Medicine, University of Zürich, Zürich, Switzerland,
2
Laboratory of Vascular Immunology, University Hospital Zürich, Zürich,
Switzerland
In Vivo Investigation of Stented Monoleaflet PGA‐P4HB Based Valves in The
Arterial Circulation of a Rat Model
Agnieszka Ksiazek1, Benedikt Weber1, Katharyn Mitchell2, Colin Schwarzwald2,
Simon Peter Hoerstrup1
1
Swiss Center for Regenerative Medicine, University Hospital of Zurich, Zurich,
Switzerland, 2Equine Department, Clinic for Equine Internal Medicine, Vetsuisse
Faculty, University of Zurich, Zurich, Switzerland
Acellular Mitral Valve Scaffold with Intact Annulus and Chordae Tendinae for
Tissue Engineering
Cristopher deBorde1, Lee Sierad1, Sourav Patnaik2, Jun Liao2, Agneta Simionescu1
1
Clemson University, Clemson, SC, USA, 2Mississippi State University, Starkville, MS,
USA
Whole Aortic Root Decellularization and Recellularization: An Elusive Task in
Heart Valve Tissue Engineering
Leslie Sierad1 ,2, Eliza Shaw1, Rebekah Odum1, Allison Kennamer1, Marius Harpa2,
Ovidiu Cotoi2, Terezia Preda2, Lucian Harceaga2, Victor Raicea2, Imre Egyed2,
Zoltan Pavai2, Annamaria Szanto2, Horatiu Suciu2, Klara Branzaniuc2, Radu Deac2,
Agneta Simionescu1 ,2, Dan Simionescu1 ,2
1
Clemson University, Clemson, SC, USA, 2University of Medicine and Pharmacy,
Targu Mures, Romania
Reasons Of Reoperation After The Ross Procedure In Different Age Groups ‐ A
Report From The German Ross Registry
Doreen Richardt1, Wolfgang Hemmer2, Armin Gorski3, Ulrich Franke4, Sigmar
Sachweh5, Arlindo Riso5, Jürgen Hörer6, Rüdiger Lange6, Anton Moritz7, Roland
Hetzer8, Michael Huebler9, Ulrich Stierle1, Hans‐Hinrich Sievers1
1
UKSH, Campus Luebeck, Department of Cardiac and Thoracic Vascular Surgery,
Luebeck, Germany, 2Sana Clinic Stuttgart, Department of Cardiac Surgery,
Stuttgart, Germany, 3University Clinic of Wuerzburg, Department of Cardiac and
Thoracic Aortic Surgery, Wuerzburg, Germany, 4Robert‐Bosch‐Hospital Stuttgart,
Department of Cardiac Surgery, Stuttgart, Germany, 5Universitäres Herzzentrum
Hamburg, Hamburg, Germany, 6Deutsches Herzzentrum Muenchen, Muenchen,
Germany, 7University Clinic Frankfurt, Frankfurt, Germany, 8Deutsches
Herzzentrum Berlin, Berlin, Germany, 9Universitätshospital Zuerich, Zuerich,
Switzerland
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Thursday 11th September
8.30‐10.30
8.30‐9.00
9.00‐9.15

9.15‐9.30

Session 6 – Intelligent Scaffolds
Chairs: Jerome Sohier & Ibrahim El Sherbiny
Keynote Lecture: Karen Wooley (Texas AM University)
C23 Peptide Amphiphiles Induced Collagen Production In Adipose Derived Stem
Cells In Relation To Tissue Engineering Application
Yuan‐Tsan Tseng1 ,2, Navaneethakrishnan Krishnamoorthy1 ,2, Ivan Carubelli1,
Jerome Sohier3, Ann McCormack2, Padmini Sarathchadra2, Adrian Chester2,
Magdi Yacoub1 ,2
1
Qatar Cardiovascular Research Center (QCRC), Qatar Foundation, Doha,
Qatar, 2The Magdi Yacoub Institute, Imperial College London, London, UK,
3
3Centre National de la Recherche Scientifique, Lyon, France
C24 A Collagen‐Glycosaminoglycan‐Fibrin Scaffold For Heart Valve Tissue
Engineering Applications
Claire Brougham1 ,2, Stefan Jockenhoevel3 ,4, Thomas Flanagan5, Fergal O'Brien1
,6
1

9.30‐9.45

C25

9.45‐10.00

C26

10.00‐10.15

C27

10.15‐10.30

C28

Tissue Engineering Research Group, Department of Anatomy, Royal College of
Surgeons in Ireland, Dublin, Ireland, 2School of Mechanical & Design
Engineering, Dublin Institute of Technology, Dublin, Ireland, 3Department of
Tissue Engineering & Textile Implants, AME‐Institute of Applied Medical
Engineering, Helmholtz Institute, RWTH Aachen University, Aachen, Germany,
4
Institut für Textiltechnik, RWTH Aachen University, Aachen, Germany, 5School
of Medicine & Medical Science, University College Dublin, Dublin, Ireland,
6
Advanced Materials & Bioengineering Research (AMBER) Centre, RCSI & TCD,
Dublin, Ireland
Towards Designing Multifunctional Biomimetic Scaffolds for Tissue
Engineering Heart Valves
Navaneethakrishnan Krishnamoorthy1 ,2, Yuan Tsan Tseng1 ,2, Poornima
Gajendrarao1, Adrian Chester2, Magdi Yacoub1 ,2
1
Qatar Cardiovascular Research Center, Doha, Qatar, 2Imperial College London,
National Heart and Lung Institute, Heart Science Centre, London, UK
Surface‐Immobilized LL37 Exhibits Mitogenic Effect On Endothelial Cells
Matthias Gabriel1, Robert Szulcek2, Geerten van Nieuw‐Amerongen2
1
Qatar Cardiavascular Research Center, Doha, Qatar, 2VU University Medical
Center, Amsterdam, The Netherlands
In‐Vitro Evaluation Of A Newly Developed Bio‐Hybrid Tissue Engineered
Aortic Valve Scaffold For TAVI‐Application
Jangsun Lee1, Nikolaus Thierfelder1, Fabian Koenig1 ,3, Ulrike Haas1, Cornelia
Fano2, Trixi Hollweck1, Christoph Schmitz1, Christian Hagl1, Bassil Akra1.
Medical Center Munich University, Munich, Germany, 2Institute of Textile
Technology and Process Engineering, Denkendorf, Germany, 3Institute of
Medical Engineering, Technical University of Munich, Munich, Germany,
Christoph Schmitz1, Christian Hagl1, Bassil Akra1
1
Medical
A New Single‐Body Silicone‐Polycarbonate‐Urethane/PDMS Heart Valves:
Material Characterization And Prototype Realization
Marianna Asaro1, Tamer Al Kayal1, Silvia Volpi1, Paola Losi1, Simona Celi2,
Mattia Glauber1, Giorgio Soldani1
1
National Council of Research, Institute of Clinical Physiology, Massa, Italy,
2
Scuola Superiore S’Anna, Massa, Italy
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10.30‐10.45

10.45‐12.45
10.45‐11.15
11.15‐11.30

11.30‐11.45

11.45‐12.00

12.00‐12.15

12.15‐12.30

12.30‐12.45

12.45‐13.30

Coffee break

Session 7 – New Approaches to Tissue Engineering
Chairs: Simon Hoestrup & Ulrich Stock
Keynote Lecture: Frank Baaijens (Einhoven University of Technology)
C29 Off‐the‐shelf Decellularized Tissue‐Engineered Heart Valves Repopulate and
Remodel Rapidly in Pre‐clinical Animal Models
Petra E. Dijkman1, Laura Frese1, Benedikt Weber1, Anita Driessen‐Mol2,
Maximilian Y. Emmert1, Bart Sanders2, Jacques Sherman3, Juerg
Gruenenfelder2, Nikola Cesarovic1, Volkmar Falk1, Peter Zilla3, Frank P.T.
Baaijens2, Simon P. Hoerstrup1 ,2
1
University and University Hospital Zurich, Division of Surgical Research, Zurich,
Switzerland, 2Eindhoven University of Technology, Department of Biomedical
Engineering, Eindhoven, The Netherlands, 3Cardiovascular Research Unit, Cape
Heart Centre, University of Cape Town, Cape Town, South Africa
C30 Improved geometry of decellularized tissue engineered heart valves for
future enhanced long term in vivo performance
B. Sanders1, S. Loerakker1, A. Driessen‐Mol1, E.F. Fioretta1, P.E. Dijkman2, L.
Frese2, S.P. Hoerstrup2 ,1, F.P.T. Baaijens1
1
Eindhoven University of Technology, Eindhoven, The Netherlands, 2University
and University Hospital Zurich, Zurich, Switzerland
C31 Tubular Heart Valves Fabricated From Decellularized Engineered Tissue
Tubes
Robert Tranquillo, Zeeshan Syedain, Jay Reimer, Jill Schmidt, Lee Meier
Univ. of Minnesota, Minneapolis, MN, USA
C32 Influence Of Small Intestinal Submucosa (SIS) Configuration On Tricuspid
Valve Remodeling After Three Months In An Ovine Model
Anna Fallon1, James Cox2, Robert Matheny1
1
CorMatrix Cardiovascular, Roswell, GA, USA, 2Washington University, St.
Louis, MO, USA
C33 Tissue‐Engineered Heart Valves with a Tubular Leaflet Design for
conventional and minimally invasive implantation
Nuno Alves1, Ricardo Moreira1, Miriam Weber1, Valentine Gesché2, Thomas
Schmitz‐Rode1, Julia Frese1, Stefan Jockenhövel1 ,2, Petra Mela1
1
AME‐Helmholtz Institute for Biomedical Engineering, RWTH Aachen
University, Aachen, Germany, 2Institut für Textiltechnik, RWTH Aachen
University, Aachen, Germany
C34 Mechanical Conditioning Of Cell Seeded PCL Fibers Under Pulsatile Pressure
Ivan Carubelli1, Jerome Sohier2, Ann McCormack1, Padmini Sarathchandra1,
Adrian Chester1, Magdi Yacoub1
1
Magdi Yacoub Institute, Harefield Heart Science Centre, Imperial College
London, Harefield, UK, 2Laboratory of Tissue Biology and Therapeutic
Engineering (LBTI), UMR 5305, CNRS, Lyon, France
Lunch

15

13.30‐15.30
13.30‐14.00
14.00‐14.15

14.15‐14.30

14.30‐14.45

14.45‐15.00

15.00‐15.15

15.15‐15.30

15.30‐15.45

Session 8 – Immuntolerance for tissue engineering applications
Chairs: Jane Grande‐Allen & Herman Waldman
Keynote: Kathy Liu (Harvard University)
C35 Minimization of Human Allograft Immunogenicity by Ice‐free
Cryopreservation
Kelvin G.M. Brockbank1 ,2, Lia H. Campbell1, Zhenzhen Chen1, Elizabeth D.
Greene1, Ulrich A. Stock3, Martina Seifert4
1
Cell & Tissue Systems, Inc., North Charleston, South Carolina, USA,
2
Department of Regenerative Medicine and Cell Biology, Medical University of
South Carolina, Charleston, South Carolina, USA, 3Department of Thoracic,
Cardiac and Vascular Surgery University Hospital Frankfurt, Frankfurt am
Main, Germany, 4Institute of Medical Immunology and Berlin‐Brandenburg
Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin, Berlin,
Germany
C36 Histological Change of A Novel Autologous Tissue Engineered Heart Valve
after Implantation
Yoshiaki Takewa1, Yasuhide Nakayama1, Hirohito Sumikura1, Satoru
Kishimoto1, Kazuma Date1, Keiichi Kanda2, Tsutomu Tajikawa3, Takaharu
Tanaka4, Eisuke Tatsumi1
1
National Cerebral and Cardiovascular Center, Osaka, Japan, 2Kyoto Prefectural
University of Medicine, Kyoto, Japan, 3Kansai University, Osaka, Japan,
4
GOODMAN Co,.Ltd., Aichi, Japan
C37 Dynamic Relationship between the Mitral Annulus and the Basal Left
Ventricular Myocardium in the Beating Ovine Heart
Matts Karlsson1, Neil Ingels2
1
Linköping University, Linköping, Sweden, 2Stanford University, Palo Alto, CA,
USA
C38 Canonical and Non‐canonical TGFβ Inhibition Differentially Regulate Matrix
Homeostasis in Porcine Aortic Valve Interstitial Cells
Varun Krishnamurthy, Andrew Stout, Kristi Lim, David Allison, K. Jane Grande‐
Allen
Rice University, Houston, TX, USA
C39 A computational approach for in situ estimation of aortic valve interstitial
cell mechanical state from tissue level measurments
Rachel M. Buchanan1, Michael S. Sacks1, 1Center for Cardiovascular Simulation
Institute of Computational Engineering and Sciences Department of Biomedical
Engineering University of Texas at Austin, Austin, USA
C40 Mimicking Heart Valve Disease In An Ex Vivo Flow Model
Boudewijn Kruithof1 ,2, Samuel Lieber3, Marianna Kruithof‐de Julio1, Vinciane
Gaussin2, Marie‐José Goumans1
1
Leiden University Medical Center, Leiden, The Netherlands, 2University of
Medicine and Dentistry of New Jersey, Newark, USA, 3New Jersey Institute of
Technology, Newark, USA
Coffee break
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15.45‐17.15
15.45‐16.15
16.15‐16.30

16.30‐16.45

16.45‐17.00

Session 9 – Gene Expression & Biomarkers in Valve Disease
Chairs: Elena Aikawa & Najma Latif
Keynote Lecture: Dennis Cokkinos (Academy of Athens)
C41 Bicuspid Aortic Valve: Determining Susceptibility for Dilation of the
Ascending Aorta by Histopathology
Nimrat Grewal1, Adriana C. Gittenberger‐de Groot1, Robert J.M. Klautz1,
Robert E. Poelmann1, Marie‐José Goumans1, Sjoerd N. Duim1, Johannes H.N.
Lindeman1, Monique R.M. Jongbloed1, Salah A. Mohamed2, Hans‐Hinrich
Sievers2, Ad J.J.C. Bogers3, Marco C. DeRuiter1
1
Leiden University Medical Center, Leiden, The Netherlands, 2University of
Lübeck, Lübeck, Germany, 3Erasmus University Medical Center, Rotterdam, The
Netherlands
C42 Second Harmonic Generation Microscopy For Analysis Of Collagen Fiber
Alterations In Calcific Aortic Valve Disease
Heather Hutson, Kristyn Masters
University of Wisconsin, Madison, Wisconsin, USA
C43 Comparative in vivo analysis of ovine tissue‐engineered heart valves re‐
endothelialized with ECs derived either from umbilical cord blood or
peripheral blood
Karolina Theodoridis1, Anna‐Lena Wendland2, Igor Tudorache1, Serghei
Cebotari1, Alexandru Mogaldea1, Tobias Goecke1, Samir Sarikouch1, Tanja
Meyer1, Doreen Unger1, Karl‐Heinz Waldmann2, Axel Haverich1, Andres
Hilfiker1
1
Hannover Medical School, Division of Thoracic and Cardiovascular Surgery,
Hannover, Germany, 2University of Veterinary Medicine, Clinic for Swine, Small
Ruminants, Forensic Medicine and Ambulatory Service, Hannover, Germany

17.00‐17.15

Expression and activity of extracellular ectoenzymes (CD39 and CD73) in
aortic valves cells and in endothelial cells under the shear stress conditions
Ewa Kaniewska1, Alicja Sielicka1, Padmini Sarathchandra2, Iwona Pelikant‐
Malecka1, Adrian Chester2, Magdi H. Yacoub2, Ryszard T. Smolenski1
1
Medical University of Gdansk, Gdansk, Poland, 2Heart Science Centre, Imperial
College London at Harefield Hospital, London, UK

20.00‐23.00

Conference Dinner –Aboard the Pride of London while cruising on the River
Thames
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Friday 12th September
8.30‐10.30
8.30‐9.00
9.00‐9.15

9.15‐9.30

9.30‐9.45

9.45‐10.00

10.00‐10.15

Session 10 – The Ross Procedure
Chairs: Jane Sommerville & Giovanni Battista Luciani
Keynote Lecture: Ismail El‐Hamamsy (Montreal Heart Institute)
C45 Reoperation Rate After The Ross Procedure Compared To Bioprostheses In
Different Age Groups ‐ A Report From The German Ross Registry
Doreen Richardt1, Wolfgang Hemmer2, Armin Gorski3, Ulrich Franke4, Sigmar
Sachweh5, Arlindo Riso5, Jürgen Hörer6, Rüdiger Lange6, Anton Moritz7, Roland
Hetzer8, Michael Huebler9, Ulrich Stierle1, Hans‐Hinrich Sievers1
1
UKSH, Campus Luebeck, Department of Cardiac and Thoracic Vascular
Surgery, Luebeck, Germany, 2Sana Clinic Stuttgart, Department of Cardiac
Surgery, Stuttgart, Germany, 3University clinic of Wuerzburg, Department of
Cardiac and Thoracic Aortic Surgery, Wuerzburg, Germany, 4Robert‐Bosch‐
Hospital Stuttgart, Department of Cardiac Surgery, Stuttgart, Germany,
5
Universitäres Herzzentrum Hamburg, Hamburg, Germany, 6Deutsches
Herzzentrum München, München, Germany, 7University Clinic Frankfurt,
Frankfurt, Germany, 8Deutsches Herzzentrum Berlin, Berlin, Germany,
9
Universitätshospital Zuerich, Zuerich, Switzerland
C46 Decellularized Valves For RVOT Reconstruction During The Ross Operation ‐
Should Cryopreservation Be Abandoned?
Francisco Costa1 ,2, Eduardo Mendel2, Ana Beatriz Costa1, Marcia Olandoski1,
Daniele Fornazari2, Sergio Lopes1, Tiago Fernandes1, Andrea Ferreira1,
Claudinei Colatusso1
1
Santa Casa de Curitiba, Curitiba, Parana, Brazil, 2Instituto de Neurologia e
Cardiologia de Curitiba, Curitiba, Parana, Brazil
C47 A multicenter evaluation of the autograft procedure for young patients
undergoing aortic valve replacement: Results from the German Ross Registry
Hans‐Hinrich Sievers1, Ulrich Stierle1, Marc Albert2, Ulrich Franke2, Armin
Gorski3, Efstratios Charitos1, Roland Hetzer4, Jürgen Hörer5, Rüdiger Lange5,
Anton Moritz6, Arlindo Riso7, Jörg Sachweh7, Wolfgang Hemmer8
1
University of Lübeck, Lübeck, Germany, 2Robert‐Bosch‐Hospital, Stuttgart,
Germany, 3University of Würzburg, Würzburg, Germany, 4German Heart
Center, Berlin, Germany, 5German Heart Center, Munich, Germany, 6University
Clinic of Frankfurt am Main, Frankfurt am Main, Germany, 7University of
Hamburg, Hamburg, Germany, 8Sana Heart Surgery, Stuttgart, Germany
C48 An Assessment of Shape and Function of the Pulmonary Autograft 10 or
more Years after the Ross Procedure
Ryo Torii1 ,2, Michael Ibrahim3, Tarun Mittal4, Mohamed Donya5, Ismail El‐
Hamamsy3, Su‐Lin Lee3, Yun Xu3, Magdi Yacoub3 ,2
1
University College London, London, UK, 2Qatar Cardiovascular Research
Centre, Doha, Qatar, 3Imperial College London, London, UK, 4Harefield Hospital,
Harefield, UK, 5Aswan Heart Centre, Aswan, Egypt
C49 Decellularized valve allografts combined with vascularized autologous small
intestine for the reconstruction of the right ventricular outflow tract (RVOT)
Karolina Theodoridis1, Serghei Cebotari1, Igor Tudorache1, Dagmar Hartung2,
Tanja Meyer1, Anatol Ciobutaru1, Alexandru Mogaldea1, Axel Haverich1,
Andres Hilfiker1
1
Hannover Medical School, Division of Thoracic and Cardiovascular Surgery,
Hannover, Germany, 2Hannover Medical School, Institute for Diagnostic and
Interventional Radiology, Hannover, Germany
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10.15‐10.30

10.30‐11.00
11.00‐13.00
11.00‐11.30
11.30‐11.45

11.45‐12.00

12.00‐12.15

12.15‐12.30

12.30‐12.45

C50

Outcome Of Pregnancy After The Ross Operation ‐ A Report From The
German‐Dutch Ross Registry
Doreen Richardt1, Wolfgang Hemmer2, Armin Gorski3, Ulrich Franke4, Sigmar
Sachweh5, Arlindo Riso5, Jürgen Hörer6, Rüdiger Lange6, Anton Moritz7, Roland
Hetzer8, Michael Huebler9, Ad JJC Bogers10, Johanna JM Takkenberg10, Ulrich
Stierle1, Hans‐Hinrich Sievers1
1
UKSH, Campus Luebeck, Department of Cardiac and Thoracic Vascular
Surgery, Luebeck, Germany, 2Sana Clinic Stuttgart, Department of Cardiac
Surgery, Stuttgart, Germany, 3University Clinic of Wuerzburg, Department of
Cardiac and Thoracic Aortic Surgery, Wuerzburg, Germany, 4Robert‐Bosch‐
Hospital Stuttgart, Department if Cardiac Surgery, Stuttgart, Germany,
5
Universitäres Herzzentrum Hamburg, Hamburg, Germany, 6Deutsches
Herzzentrum Muenchen, Muenchen, Germany, 7University Clinic Frankfurt,
Frankfurt, Germany, 8Deutsches Herzzentrum Berlin, Berlin, Germany,
9
Universitätsspital Zuerich, Zuerich, Switzerland, 10Erasmus University Medical
Center Rotterdam, Rotterdam, The Netherlands
Coffee Break

Session 11 – Valve Conserving Operations ‐ From Structure to Function
Chairs: Axel Haverich & Magdi Yacoub
Keynote: Martin Misfeld (Liepzig)
C51 Haemodynamics in Anatomically Shaped Sinus Prostheses Analysed by 4D
Flow MRI
Thekla Oechtering1, Michael Beldoch1, Claudia Schmidtke2,3, Michael
Scharfschwerdt2, Peter Hunold1, Jörg Barkhausen1, Alex Frydrychowicz1, Hans‐
H. Sievers2, 1Clinic for Radiology and Nuclear Medicine, UKSH, Lübeck,
Germany, 2Department of Cardiac and Cardiothoracic Surgery, UKSH, Lübeck,
Germany, 3Separtment of Cardiac Surgery, Segeberger Clinic, Bad Segeberg,
Germany
C52 Aortic Valve Dynamics After Valve‐sparing Procedure With The New ‘Sinus’
Prosthesis Used For Valve Sparing Aortic Root Replacement
Claudia Schmidtke, Hans‐H. Sievers
Klinik für Herz‐ und thorakale Gefässchirurgie, Universitätsklinikum SH,
Campus Lübeck, Lübeck, Germany
C53 In Vitro Analysis of The Alterations Produced by Transcatheter Aortic Valve
in The Valsalva Sinuses
Andrea Ducci, Francesco Pirisi, Spyridon Tzamtzis, Gaetano Burriesci
University College London, London, UK
C54 Aortic valve replacement with decellularized aortic allografts: First clinical
results
Igor Tudorache, Anatol Ciubotaru, Thomas Breymann, Samir Sarikouch,
Dietmar Boethig, Alexander Horke, Luitgard Meschenmoser, Serhhei Cebotari,
Axel Haverich
Medizinische Hochschule Hannover, Hannover, Germany
C55 Patient‐Specific Finite Element Modeling of Ascending Thoracic Aortic
Aneurysm Using In Vivo Magnetic Resonance Imaging
Liang Ge, Michael Hope, David Saloner, Andrew Wisneski, Kapil Krishnan,
Julius Guccione, Elaine Tseng
University of California San Francisco Medical Center, San Francisco, CA, USA
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12.45‐13.30

Session 12 – Taking Cardiac Surgery to the People
Chair: Jane Sommerville

12.45‐13.30

Keynote Speaker: Magdi Yacoub (Imperial College London)

13.30‐13.40

Concluding remarks and adjourn for Lunch
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Abstracts – Oral Presentations
C1
Extracellular Matrix Composition Regulates Endothelial to Mesenchymal
Transformation
Sudip Dahal1, Jonathan Bramsen1, Peter Huang2, Gretchen Mahler1
1
Binghamton University, Department of Bioengineering, Binghamton, NY, USA,
2
Binghamton University, Department of Mechanical Engineering, Binghamton,
NY, USA
Endothelial to mesenchymal transformation (EndMT) is a valve
morphogenic mechanism associated with aortic valve regeneration and
disease initiation. The aortic valve fibrosa is the initial site of
inflammatory and calcific degeneration, and EndMT occurs on the valve
fibrosa local to calcified nodules. In healthy valves, the fibrosa matrix is
primarily composed of circumferentially-aligned, collagen fibers. Valve
disease is characterized by the deposition of chondroitin sulfate and
dermatan sulfate-rich proteoglycans into the sub-endothelial fibrosa
layer, and the presence of the glycosaminoglycan (GAG) hyaluronan
near calcified nodules. The goal of our work is to identify if and how this
altered extracellular matrix (ECM) composition promotes EndMT and
eventual calcification. In this study we examined aortic valve endothelial
cell response to ECM changes using in vitro cell cultures and hybrid
continuum-stochastic modeling. Our in vitro results show that the
addition of GAGs (chondroitin sulfate, dermatan sulfate, and hyaluronan)
to a 3D collagen I-based matrix strongly induces EndMT. Our
computational model captures EndMT and cell migration within the local
ECM environment. The composition, structure, and mechanical behavior
of the ECM are expressed in the adhesion stresses during stochastic
EndMT and resistance to biased cell migration. The model has been
developed to contain measurable quantities validated by our in vitro
experimental data and to predict which cell-ECM interactions are critical
to mesenchymal transformation and cell migration. Determining the
matrix cues that induce and promote EndMT will advance tissue
regeneration strategies, tissue engineering approaches, and
understanding of in vivo endothelial cell behavior in valve disease
progression.
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C2
Cyclic stretch orchestration of RhoA‐Rac1 signaling axis is essential for
embryonic valve remodeling
Russell Gould1, Huseyin Cagatay2, Joanna MacKay3, Sanjay Kumar3, Jonathan
Butcher1
1
Cornell University, Ithaca, NY, USA, 2Dogus University, Istanbul, Turkey,
3
University of California, Berkeley, Berkeley, CA, USA
Embryonic valves rapidly evolve from disorganized globular “cushions”
to highly organized thin fibrous leaflets. These multi-scale interactions
occur within a demanding hemodynamic environment and are essential
to maintain unidirectional flow. The mechanisms by which mechanical
forces direct cellular response to coordinate this cycle of morphogenesis
and function are not known. In this study, we determined how
mechanosensitive small GTPases RhoA and Rac1 coordinate
atrioventricular valve (AV) differentiation and morphogenesis. RhoA
activity is elevated during early cushion formation, but decreases
considerably over development. In contrast, active Rac1 increases as
cushions mature into valves. Using gain and loss of function assays, we
determined that the RhoA-SRF pathway was essential for a
myofibroblastic contractile phenotype in early cushion formation, but was
surprisingly insufficient to drive matrix condensation during valve
maturation. Instead, sustained cyclic stretch was a potent inhibitor of
myofibroblastic activation by decreasing RhoA-GTP levels, and
promoted a Rac1 signaling “switch” via nuclear membrane localization of
FilGAP. The downstream Rac1-p38 pathway was necessary and
sufficient to cause directed matrix condensation through cell polarization,
leading to enhanced stress fiber alignment and adhesion necessary for
valvular remodeling. Finally, we used partial atrial ligation experiments
to show that altered cyclic mechanical loading in vivo augmented or
restricted cushion growth directly through potentiation of RhoA and Rac1
activity. Together, these results demonstrate that mechanical signaling is
essential to coordinate a transition from RhoA to Rac1 based signaling,
to produce a thin organized leaflet with a quiescent phenotype.
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C3
Insights Into Regional Adaptations In The Growing Pulmonary Artery Using A
Meso‐scale Structural Model: Effects Of Ascending Aorta Impingement
Michael Sacks
Institute of Computational Engineering and Sciences Department of Biomedical
Engineering University of Texas at Austin, Austin, USA
Delineating the normal postnatal development of the pulmonary artery
(PA) and valve can inform our understanding of congenital
abnormalities. Utilizing the extensive experimental structural and
mechanical measurements from our previous study, we developed a
structural constitutive model for the growing PA at the juvenile and adult
stages. Our key findings were that while there are regional variations
with age, the major effects of the age related changes were exhibited in
the medial aspect of the PA wall. Specifically, we observed that
structurally, the elastin and collagen fibers' in-plane splay underwent
opposite changes, and a trend towards more rapid collagen fiber
recruitment with respect to strain. The most profound changes were
observed with the fiber moduli, with the elastin modulus increasing by
~50% and the collagen modulus reducing to only ~25% of the juvenile
value. As observed in our geometric studies the focal changes observed
in the medial region are likely due to the impingement of relatively stiff
ascending aorta on the growing PA. Clearly, during the postnatal
somatic growth, local stresses can substantially modulate the
development of regional tissue microstructure and mechanical behaviors
in the PA. Finally, we underscore that in our previous studies suggest an
increase in effective PA wall stress with postnatal maturation. This
observation is contrary to the accepted theory of maintenance of
homeostatic stress levels in the regulation of vascular function, and
suggests alternative mechanisms regulate postnatal somatic growth.
ACKNOWLEDGMENTS
This research was supported by NIH grant R01 HL-089750.
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C4
Modulation Of Human Valve Interstitial Cell Phenotype and Function Using A
FGF2 Formulation
Najma Latif1 ,2, Alfred Quillon1, Ann McCormack1, Alec Lozanoski1, Magdi
Yacoub1 ,2, Adrian Chester1 ,2
1
Imperial College, London, UK, 2Qatar Cardiovascular Research Centre, Doha,
Qatar
Valve interstitial cells comprise the main fibroblastic component of valve
leaflets however in culture it is accepted that they differentiate into a
myofibroblastic phenotype. A fibroblast culture media (FIB) formulation
was assessed for its ability to maintain the fibroblastic phenotype.
Normal human VICs were cultured in standard DMEM and in FIB
consisting of FGF2 (10ng/ml), insulin (50ng/ml) and 2% FCS for at least
one week. VICs in DMEM exhibited large, spread cells whereas VICs in
FIB were smaller, elongated and spindly. Aspect ratio and size were
both significantly higher in DMEM (p<0.01). The level of expression of αSMA was significantly reduced in DMEM (p<0.01). There was a
significant decrease in the proliferative potential of VICs in FIB after 1
(p<0.05) and 2 (p<0.01) weeks in culture. Contraction of collagen gels
was significantly reduced in FIB from 4 hours post dislodgment (p<0.05).
Focal adhesions were assessed in relation to this contraction and VICs
were found to have significantly fewer supermature (p<0.001) and
smaller focal adhesion (p<0.01) in FIB. VICs in FIB demonstrated a
slower migratory ability after wounding at 72 hours (p<0.01). Treatment
of human VICs with this FIB formulation has the ability to dedifferentiate
the VICs back to a fibroblastic phenotype with phenotypic and functional
characteristics ascribed to quiescent VICs. The use of quiescent VICs in
the study of normal valve biology, pathology and in the field of tissue
engineering important to recapitulate the physiological properties of VICs
in vitro.
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C5
Deletion of Krox20 results to bicuspid aortic valve
Gaelle Odelin1 ,2, Emilie Faure1 ,2, Corinne Maurel‐Zaffran1 ,3, Fanny Coulpier4 ,5,
Piotr Topilko4 ,5, Patrick Charnay4 ,5, Stéphane Zaffran1 ,2
1
Aix Marseille Universite, Marseille, France, 2INSERM GMGF U910, Marseille,
France, 3CNRS, IBDML UMR7288, Marseille, France, 4INSERM U1024, IBENS,
ENS, Paris, France, 5CNRS, UMR8197, IBENS, ENS, Paris, France
Aortic valve disease may be life threatening and is highly prevalent
conditions in Western countries whose impact is continuously increasing
in the aging population. Among the aortic valve disease, bicuspid aortic
valve (BAV) occurs when the aortic valve has two cusps, rather than
three, and represents the most common form of congenital cardiac
malformation, affecting 1-2% of the population. Despite the clinical
significance of this pathology, its etiology is poorly understood. To date,
only few genes (as NOTCH1, HOXA1 or TGFBR2) have been
associated with BAV. Our recent work showed that the transcription
factor Krox20 is expressed in the mesenchymal cells of the aortic valves
of embryo and adult mice. Krox20 mutant embryos develop abnormal
aortic valves with hypercellularization of interstitial cells and
disorganization of the extracellular matrix (ECM). Our data revealed that
aortic valve defect is caused by increased contribution of cardiac neural
crest-derived cells and direct downregulation of fibrillar collagen Col1a1
and Col3a2 genes. Here, we report that 25% of Krox20 mice have BAV.
This defect is essentially due to a failure of normal development of the
embryonic cushions in the outflow tract resulting in a fused right- and
non-coronary cusp. Our analysis shows that Krox20 regulated
transcriptional levels of eNos (endothelial nitric oxide synthase), which is
required for endothelial differentiation and vascular remodeling. We are
currently analyzing the genetic interaction between Krox20 and eNos.
Thus, Krox20 is a candidate gene for human aortic valve disease such
as BAV.
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Pharmacological Treatment in Marfan Mitral Valve:A Pilot Study
Alexander Black1, Vincent Griffiths1, Dalibor Soukup2, Jonathan McGuinnes3,
Darren McLoughlin3, John Byrne3, Mark Redmond3, Harry C. Dietz4, Peter
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Marfan syndrome is caused by mutations in the gene that encodes
fibrillin-1. Mitral valve prolapse is a cardiovascular complication in
Marfan patients. This study examined the mitral valve of normal controls,
untreated Marfan mice (using the murine model of Marfan syndrome,
C1039G) and Marfan mice treated with either: Pravastatin (100mg/kg);
Losartan (60mg/kg) or Doxycycline (24mg/kg). Valves were analysed
both ultrastructurally and stereologically.
The C1039G murine model of Marfan Syndrome exhibits ultrastructural
changes in the mitral valve compared to control animals. These include
aberrant collagen orientation and phenotypic change to Valvar Interstitial
Cells (VIC). Pharmacological treatment of the Marfan mouse is seen to
change the microanatomy of the mitral valve; using transmission
electron microscopy and a variety of stereological techniques these
changes are demonstrable and quantifiable. Of the three
pharmacological treatments used, pravastatin is the only one to
decrease mitral cusp thickness whilst both Doxycycline and Losartan
increase valve thickness in µm (40.96 +/-13.26) above the level of
Marfan Syndrome - itself thicker than the control. This may have
implications in valve stiffness and compliance during the cardiac cycle.
Marfan Syndrome and each treatment group exhibited an increase in the
absolute volume of VIC per µm3 (221.29 +/-59.49), VIC nucleus (101.82
+/-25.41)and VIC rER (27.24 +/-11.51) compared to control. VIC and
VIC rER was greatest in the pravastatin treated group. This may suggest
that pravastatin treatment of Marfan Syndrome mice may have a
beneficial effect on protein production by VICs in the mitral valve,
thereby supporting valvar function and tonicity.
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COX2 Inhibition Reduces Aortic Valve Calcification In Vivo
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Calcific aortic valve disease (CAVD) is characterized by calcific nodule
formation, stenosis of the valve, and induction of an osteogenic gene
program. Klotho-deficient mice were used to study the molecular
mechanisms and cellular origins of CAVD as they develop robust aortic
valve (AoV) calcification. Through microarray analysis of AoV tissues
from klotho-deficient and wild type mice, increased expression of the
gene encoding cyclooxygenase 2 (COX2) was found. Aside from a role
in inflammation, COX2 activity contributes to bone differentiation and
homeostasis. Thus, we hypothesize that COX2 has a critical role in AoV
calcification. In klotho-deficient mice, COX2 expression is increased
throughout regions of AoV calcification in the valve interstitial cells
(VICs). Similarly, COX2 expression is increased in human CAVD. To
determine if the developmental origin of VICs confers a unique potential
to calcify, the contribution of endothelial versus neural-crest derived
VICs to the calcified area was assessed in klotho-deficient mice. COX2expressing VICs in calcified regions were primarily of neural crest origin
and rarely of endothelial origin, suggesting that neural crest derived
VICs activate COX2 gene expression and have the capacity to calcify.
Treatment of cultured porcine VICs with osteogenic media induced bone
marker gene expression, which was blocked by inhibition of COX2
activity. Furthermore, genetic loss of function or pharmacological
inhibition of COX2 activity reduced AoV calcification and blocked
osteogenic gene induction in klotho-deficient mice. Thus, COX2
expression is activated in calcifying VICs of neural crest developmental
origin, and COX2 inhibition is sufficient to reduce AoV calcification in
vivo.
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Enzymes of extracellular nucleotide metabolism participate in regulatory
functions, such as immunomodulation, thromboregulation, bone
remodeling or cell proliferation by controlling extrcellular nucleotide
metabolite concentrations. In valves, disturbances of these processes
may lead to calcification. This study aimed to investigate the changes in
extracellular nucleotide metabolism in pathology of human aortic valves.
Stenotic aortic valves were obtained from patients after aortic valve
replacement (n=100) and non-stenotic valves were obtained after heart
transplantation or Bentall procedure (n=20). Valves were analyzed for
ecto-nucleoside triphosphate diphosphohydrolase (eNTPD), ecto-5’nucleotidase (e5NT) and ecto-adenosine deaminase (eADA) activities
by exposing specific area of fibrosa or ventricularis side to medium with
nucleotide substrates and tracing conversions by high perfomance liquid
chromatography. These measurements were correlated with clinical
data.
On the fibrosa of stenotic aortic valve, activities of eNTPD, e5NT and
eADA were 1.80±0.09, 1.11±0.06, 0.95±0.07 nmol/min/cm2 respectively.
Whereas, in the non-stenotic valves these activities were higher:
2.60±0.32 (eNTPD) and 2.11±0.21 (e5NT) or lower: 0.55±0.09
nmol/min/cm2 (eADA). No differences between stenotic and non-stenotic
valves were observed on the ventricular side. Negative correlations were
found between: eNTPD and e5NT activities and plasma low density
lipoproteins as well as between eADA activity and ejection fraction.
Positive correlation was demonstrated beetween eADA activity and left
ventricular end-systolic diameter.
These results demonstrate that extracellular nucleotide breakdown in the
valve is adversely modified in aortic stenosis. Diminished activities of
eNTPD and e5NT with increase in eADA activity may affect extracellular
nucleotide concentrations in the way that favors valve inflammation and
calcification.
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Characterisation of human cardiovascular tissue affected by calcific disease
using Raman and scanning electron microscopy
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Certain pathological processes give rise to ectopic soft tissue
calcification. A better understanding of the structures and nano-scale
architecture of ectopic calcification in tissues such as aortae affected by
arteriosclerosis and other calcific diseases can lend insight into the
biomineralisation process of the different diseases. Aortae, aortic valve,
and coronary artery samples from patients and healthy human donors
were analysed using Raman spectroscopy and scanning electron
microscopy with energy-dispersive X-ray spectroscopy (SEM-EDS). A
previous study in our group identified spherical calcium phosphate
deposits within aortic tissues of diseased and even healthy donors.
These spherical deposits were a highly crystalline form of calcium
phosphate1, 2. In this study, further characterisation with Raman
mapping of the aorta wall tissue supports these results, based on
intensity heat maps of the 960 cm-1 calcium phosphate and the 1080
cm-1 phosphate bands; indicating discreet regions of calcium phosphate
deposits within the tunica media of the aortic wall tissue. Furthermore,
the mineral composition of the calcified spheres was determined to be
magnesium-substituted hydroxyapatite, as found by Raman, EDS, and
ICP, in stark contrast to calcification of atherosclerotic plaques and bone
mineral, which are poorly crystalline apatite. Interestingly, this is true for
calcified spheres of the tunica media in both healthy and diseased
tissue, suggesting the same origin. This study indicates that the
calcification in vascular tissues is different from that of bone. The
characterisation and study of these tissues can thus contribute to a
better understanding of pathophysiological tissue calcification
processes.

29

C10
Analysis of The Retinoblastoma Protein In pAVIC Calcification
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Calcific aortic valve disease (CAVD) shares several features with
osteogenesis. This pathological process is similar to normal
development of bone, phenotypically and transcriptionally. Because the
retinoblastoma protein (Rb) pathway is critical to bone development, we
hypothesized that the Rb pathway also regulates development and
progression of CAVD. To test this hypothesis we cultured porcine aortic
valve interstitial cells (pAVICs) infected with lenti-viruses expressing
shRNA constructs targeting porcine Rb mRNA. Knockdown of the Rb
transcript was confirmed by qRT-PCR (80% and 69% reduced
expression by shRb1 and shRb3, respectively, p<0.005)) and we
consistently observed reduced Rb protein by Western blot compared to
a scrambled shRNA control. AVICs lacking Rb had similar ki-67 positivity
compared to control cells (21-36%, p=NS), suggesting that cell-cycle
regulation is not impaired in pAVICs with Rb knockdown. Calcification
was induced by culturing the pAVICs in medium treated with ascorbic
acid, B- glycerophosphate, and dexamethasone. After three weeks,
expression of bone-specific genes (Runx2, alkaline phosphatase,
osteocalcin and osteonectin) was increased compared to pAVICs
cultured in normal medium, as determined by qRT-PCR analysis.
Calcification, detected by alizarin red S staining, was significantly higher
in cells treated with calcification medium (p<0.05). We observed
modestly increased calcification of pAVICs transformed with the shRb3
construct compared to scrambled control. The role of pRb in pAVIC
calcification is currently under investigation both in vitro and in vivo by
cre-mediated knockout. These studies will determine the potential role
for Rb in pAVIC calcification and CAVD.

30

C11
Investigating The Role Of Matrix Vesicles In Valve Interstitial Cell
Calcification.
Lin Cui1, Dongxing Zhu1, Francesco Rao2, Colin Farquharson1, Vicky MacRae1
1
The Roslin Institute, Edinburgh, Midlothian, UK, 2Dundee Cell Products Ltd,
Dundee, UK
Accelerated progression of calcific aortic valve disease (CAVD) is
frequently observed in patients with end stage renal disease (ESRD)
however the cellular mechanisms responsible remain unclear. Elevated
serum calcium (Ca) and phosphate (Pi) levels in ESRD patients
enhance vascular smooth muscle cell calcification and the subsequent
release of matrix vesicles (MV), which are specialised structures that
initiate mineral nucleation. In the present study, we determined whether
valve interstitial cells (VICs) contribute to aortic valve calcification
through the release of MVs.
Rat VICs were cultured with control medium or calcifying medium
containing 2.7 mM Ca and 2.5mM Pi (Ca x Pi) for 3 days. A significant
increase in calcium deposition was observed (10.8 fold, P<0.001) by
quantitative calcium assay and alizarin red staining. In addition, elevated
levels of Ca x Pi significantly increased the mRNA expression of
calcification regulators PiT-1 (1.6 fold, P<0.01), Enpp1 (2.9 fold, P<0.01)
and Phospho1 (2.6 fold, P<0.001). However, the expression of the
osteogenic markers Runx2, Ocn, and Msx2 were unaltered. MVs
released by rat VICs were harvested by ultracentrifugation. Western
blotting revealed that MVs released through Ca x Pi stimulation showed
increased expression of the MV markers Annexin 2 and Annexin 6.
These studies are the first to establish the in vitro calcification of rat VICs
as a model of CAVD. Our data has demonstrated that calcifying VICs
release MVs, suggesting a potential novel mechanism underpinning the
pathogenesis of CAVD.
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The role of eNOS uncoupling in aortic valve disease progression is
unknown, despite its known role in vascular pathology. Here we show
that inflammation drives increased valve oxidative stress via eNOS
uncoupling, leading to endothelial dysfunction and calcification. Inhibition
of eNOS uncoupling and its effects with tetrahydrobiopterin or
superoxide dismutase can mitigate valve degeneration by blocking the
downstream effects of eNOS uncoupling.
Calcified human aortic valves expressed side-specific elevation of
superoxide levels in the endothelium, co-localized with high VCAM-1
expression, linking oxidative stress, inflammation, and valve
degeneration. TNFα treatment increased superoxide and decreased
eNOS and VE-cadherin acutely over 48 hours in aortic valve endothelial
cells (VEC) and chronically over 21 days in ex vivo AV leaflets. Cotreatment of VEC with tetrahydrobiopterin (BH4) but not apocynin
mitigated TNFα-driven VEC oxidative stress, indicating eNOS
uncoupling as the primary mechanism of increased valve endothelial
oxidative stress. Co-treatment of VEC or ex vivo AV leaflets with
TNFα+BH4 or TNFα+superoxide dismutase (SOD) rescued endothelial
function and mitigated inflammatory responses. In ex vivo AV leaflets,
TNFα additionally caused extracellular matrix disorganization,
myofibroblastic activation, and calcium and mineral deposition, which
were ameliorated by co-treatment with TNFα+BH4 or TNFα+SOD.
These results present endothelial inflammatory oxidative stress as a new
mechanism that connects early valve pathology with later stages of
degeneration. Targeting these mechanisms via tailored antioxidant
therapy could provide new avenues for treatment of CAVD.
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Male sex is a significant risk factor for developing calcific aortic valve
disease (CAVD), but this phenomenon has not previously been
investigated on the cellular scale. Cellular-scale sex-related differences
have been noted in other cardiovascular conditions, leading us to
investigate whether male and female valvular interstitial cells (VICs)
exhibit differential behavior in the context of CAVD. VIC cultures have
not previously been separated by sex, and in vitro evaluation revealed
intrinsically higher apoptosis, proliferation, and αSMA expression in male
porcine VICs compared to female VICs; all of these markers are
associated with CAVD pathobiology. Additionally, male VICs were
significantly more sensitive to treatment with TGF-beta1, an
inflammatory cytokine that plays a key role in CAVD progression. For
instance, in male VICs, αSMA was significantly increased by TGF-beta1
and decreased by a neutralizing antibody to TGF-beta1, while female
VICs were unresponsive to both treatments; endogenous TGF-beta1
production was similar across sexes. Expression of alkaline
phosphatase was significantly decreased upon TGF-beta1 treatment of
male VICs, while female VICs were unresponsive. Male VICs expressed
higher levels of TGF-beta receptor 2, which may be one mechanism by
which males exhibit increased sensitivity to this stimulus. Moreover,
equivalent levels of phosphorylated Smad2 but increased p38 MAPK
phosphorylation in male VIC cultures indicate involvement of the noncanonical TGF-beta1 signaling pathway in these sex-related differences.
The finding that male and female VICs exhibit significant cellular-scale
differences, particularly in their responsiveness to pro-disease stimuli,
has the potential to substantially impact our characterization of CAVD
etiology and possible treatments.
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Familial hypercholesterolemia (FH) is a prevalent hereditary disease
associated with coronary artery disease and increased risk of calcific
aortic valve disease (CAVD). The Rapacz familial hypercholesterolemic
(RFH) swine is a well-established model of human FH and
atherosclerosis in general, but has not been studied in the context of
CAVD. We hypothesized that these unique animals may provide insight
into CAVD pathobiology and its relationship to atherosclerosis. Coronary
arteries and aortic valves from wild-type and RFH swine (0.25, 1, 2, and
3 year-old) were characterized across multiple scales and found to
possess complex atherosclerotic lesions and hallmarks of early-stage
human CAVD, respectively. Adult RFH swine exhibited significant leaflet
thickening, increased lipid oxidation, macrophage infiltration, and
extensive extracellular matrix remodeling, including proteoglycan
enrichment, collagen disorganization, and elastin fragmentation.
Intracardiac echocardiography showed leaflet thickening in adult RFH
aortic valves, and valve function ranged from unimpaired to mildly
sclerotic. Microarray analysis of adult and juvenile RFH valves revealed
significant upregulation of inflammation-related genes and several
commonalities with atherosclerosis; pathway analysis also showed
substantial overlap of the RFH model with previous microarray
comparisons of healthy vs. diseased human valves. Overall, adult RFH
swine exhibited several hallmarks of early human CAVD that have not
previously been demonstrated in other animal models, and may help to
elucidate CAVD etiology in both FH and non-FH individuals. The
development of advanced atherosclerotic lesions but only early-stage
CAVD in RFH swine also support the hypothesis of an initial shared
disease process, with additional stimulation or co-morbidities necessary
for further progression.
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C-type natriuretic peptide (CNP), which signals through the particulate
guanylate cyclase receptor NPR2, is elevated in disease-protected
regions of the aortic valve and reduced in stenotic valves. In vitro, CNP
inhibits valvular cell myofibro/osteoblastogenesis, yet its functional
impact in vivo is unknown.
Male Npr2+/- mice and WT littermates were aged for 4 or 8 months (n =
9-15/group). Valve/cardiac function was assessed by echocardiography,
and valve matrix composition/morphology by Movat's.
4-month Npr2+/- mice developed deficits in aortic valve function, with
elevated transvalvular velocity (normalized to ejection fraction; V/EF)
(+30.7% vs. WTs, p < 0.01). V/EF was further increased in 8-month
Npr2+/- mice vs. WTs (+44.4%, p < 0.001). This was accompanied by
impaired systolic function in 8-month Npr2+/- mice: EF, fractional
shortening, and left ventricular outflow tract velocity were reduced by
22.0%, 26.9%, and 18.5%, respectively, vs. all others (p < 0.001). Npr2+/leaflets were thickened, rich in proteoglycans, and developed
collagenous remodeling of the attachment region. 9.5% of Npr2+/- mice
have congenital bicuspid aortic valves (BAVs) (none in WTs), with the
worst valve function (V/EF increased by 70.0% vs. tricuspid Npr2+/- mice,
p < 0.01), flow disturbances, most severe leaflet proteoglycan
accumulation, fibrosis, and evidence of calcification.
Thus, impaired CNP signaling produces valvular/LV dysfunction and
increases BAV incidence. These findings reveal a functional role for
CNP in the aortic valve, suggest therapeutic strategies, and establish a
novel BAV mouse model. They also broadly implicate guanylate cyclase
family signaling in valvular development, complementing evidence from
other BAV mutant mouse models.
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Myxomatous mitral valve disease (MMVD) is a pathological condition
resulting in mitral regurgitation (MR) and is only treated surgically at
present. Increasing evidence suggests that mitral valve interstitial cells
(MVICs) play a critical role in the pathological remodeling of the MV.
Serotonin (5HT) is a neurotransmitter, and if present at increased levels
can cause a valvulopathy. This suggests that 5HT-receptor (5HTR)
signaling plays a physiologic role, and that increased 5HTR activity
could mediate the pathophysiology of valve disease. Here we test the
hypothesis that 5HTR antagonism can alter the pathological prolapse of
the MV in vitro and ex vivo.
Using microarray (N=4/group) and histological analysis on human
specimens we show upregulation of serotonin receptors (5HR) 2A and
2B on MMVD patients vs. controls (+12.5 and +28.4 folds, respectively;
p-value <0.001) Immunological analysis on surgically explanted tissues
show pathological remodeling of the MV leaflets (increased thickness
and ECM accumulation) with concomitant activation of 5HT signaling
and MVIC activation (5HTR2A+, 5HTR2B+, OPN+, SMA+, RUNX2+). In
vitro assay on human isolated MVICs (6 days), as well as ex-vivo
biomechanical testing of human MV (6 days at 15% and 1 Hz using a
uniaxial tensile bioreactor), were performed with results showing that
VICs activation is associated with 5HTR activation and that 100 mm
Ketanserin (5HTR1A antagonist) reverts these effects.
It is concluded that the pathological remodeling of the MV in the setting
of myxomatous prolapse is associated with 5HT signaling. These results
could have important implications for testing therapeutic candidates
based on 5HT antagonism.
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Mitral leaflet remodeling, i.e. its expansion and fibrosis has been recently
demonstrated in ischemic heart disease(IHD), and the leaflet remodeling
capacity has been attributed to chronic leaflet tethering. In our study, we
compared the extent of leaflet remodeling in human patients with IHD ,
and compared against patients with aortic stenosis(AS) with similarsized ventricles and valve tenting. Cardiac gated phase contrast MRI
was performed in 76 humans with ischemic heart disease with mitral
regurgitation (MR severities: mild-45; severe-31) and compared with 10
humans with severe aortic stenosis with equivalent dilated ventricles.
Left ventricular volume (LVV), mitral regurgitant volume (MRV), tenting
area (TA) were measured in either groups, and leaflet remodeling was
quantified as diastolic anterior and posterior leaflet lengths (ALL,PLL)
normalized by the body surface area. LVV did not differ between
patients with IHD and AS. In IHD patients, ALL and PLL increased
significantly from mild MR to severe MR. A 25% increase in ALL from
12.5 ± 3.3 mm/m2 in mild MR to 15.6 ± 3.4 mm/m2 to severe MR
(p=0.004) was measured, while a 42% increase in PLL was measured
(p<0.001). Both ALL and PLL has a significant correlation with MRV
(ALL: r=0.37, P=0.001; PLL: r=0.42, P=0.0002), and TA. AS patients
with identical LV size, but without an infarction or regurgitation had
shorter leaflets as compared to MR patients. Leaflet remodeling is an
active process in IHD patients, and seemed to rely on the presence of
mitral regurgitation and/or a myocardial infarction.

37

C18
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Mutations in the gene encoding Filamin-A, a cytoskeletal protein, were
identified in patients with familial mitral valve prolapse(MVP). In this
study, we sought to investigate the impact of these mutations on
cultured cells in comparison with wild type Filamin-A, to delineate the
mechanisms underlying MVP.
Four immortal cell lines were established - Filamin-A KO, Filamin-A WT,
G288R mutated Filamin-A, and P637Q mutated Filamin-A. Cells were
cultured on plastic petri-dishes for a week, and at confluence the cells
were imaged under a microscope, then their 3D morphology and
mechanical stiffness measured with scanning ion conductance
microscopy, and then the cells were assayed for integrins and counted
using flow cytometry.
Filamin-A KO cells developed blebs on the surface, were flat and did not
sufficiently attach to the cell culture substrate, while WT cells
demonstrated excellent attachment and formed extensive lamellapodi
and filipodia. Both G288R and P637Q mutated cells had reduced
extensions, with a cell structure that is small in circumference but large
in height. α1, α2, α3, α5, β1, β3, β4, α5β3, α2β1 integrin expression was
drastically reduced in both G288R and P637Q mutations, compared to
WT. A 24 hour substrate attachment assay demonstrated 30%
attachment of G288R cells were attached and viable, 50% of the P637Q
cells were attached and viable, and 98% of WT cells were attached and
viable, with similar results seen in gel contraction studies.
Filamin-A mutations associated with mitral valve prolapse seem to alter
fundamental cellular mechanisms essential for cell attachment to matrix,
motility and mechanotransduction.
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The extracellular matrix (ECM) determines multiple aspects of tissue
biology. Greater understanding of ECM as an extracellular source of
cytokines mediating paracrine regulation of tissue function will better
inform tissue engineering strategies for replicating ECM biology. During
response to injury, extracellular latent TGF-β is activated and released to
mediate remodeling in many tissues. To understand how mechanical
forces regulate leaflet homeostasis, we study responses of native heart
valves to chronic changes in flow. Using an ex vivo model in which
multiple rat pulmonary valves are cultured 7-days together under flow
(cycling) or static (non-cycling) conditions, we find that leaflets remodel
in response to a chronic change in flow, accompanied by marked
changes in the expression of multiple genes. Intriguingly however, we
observed that TGF-β gene expression was unchanged between flow and
static conditions. To investigate whether activation of latent TGFβ modifies gene expression changes induced by altered mechanical
force in leaflets, valves were cultured in the presence of the TGF-βReceptor-1/Alk-5 kinase inhibitor LY2157299. We found that the
expression of genes highly regulated (4 to16-fold) in response to
chronically altered flow was markedly reduced by LY2157299 treatment:
63±15% (mean decrease±SD; n=8) from the non-drug fold-change in
gene expression. The effects of TGF-β receptor signaling inhibition on
force-regulated gene expression demonstrate the presence of leaflet
tissue-level paracrine TGF-β signaling. Amplification of mechanosensitive gene expression by extracellular TGF-β reveals a robust and
complex signaling network for the regulation of leaflet homeostasis, and
demonstrates the critical importance of the ECM in directing valve
biology.
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Aortic Valve (AV) experiences dynamic mechanical environment, which
when altered can lead to inflammation and calcification, preferentially on
fibrosa side. Using porcine AV, our ex vivo studies showed that alteredshear conditions induced inflammatory markers (ICAM-1, VCAM-1,
BMP-4) preferentially on fibrosa. This shear- and side-dependent AV
pathophysiology is attributable, in part, to the altered gene expression.
MicroRNAs (miRs) are short noncoding RNAs that post-transcriptionally
regulate gene expression and have been shown to regulate cardiac
development and disease. Previously, our microarray studies on human
AV endothelial cells showed that miRs-181a, 181b, 199a, and 214
responded differently to altered-shear conditions. It is hypothesized that
these miRs are shear- and side-dependent and regulate AV
pathophysiology by modulating inflammation, remodeling or cell death.
For ex vivo studies, fresh porcine AV tissues (n=9) were cultured in a
shear stress bioreactor for 48 hours.For altered-shear studies, fibrosa
was exposed to unidirectional pulsatile (FL: 0-80dyne/cm2) shear stress
and ventricularis was exposed to bidirectional oscillatory (VO: +/5dyne/cm2). For side-specific studies, fibrosa was also exposed to
bidirectional oscillatory shear stress. Following shear, total RNA was
isolated from 3 pooled samples and expression of miRs was determined
by qPCR (n=3). Altered-shear (FL vs VO) significantly (p<0.05)
upregulated miR-181a and downregulated miR-199a and 214, indicating
these miRs are shear-sensitive. Also miR-181a was significantly
(p<0.05) upregulated in fibrosa exposed to oscillatory shear compared to
that of ventricularis, showing side-dependency. In summary, miR-181a,
199a and 214 are shear-sensitive but not miR-181b. MiR-181a is also
side-specific which may regulate shear- and side-dependent AV
pathophysiology.
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Influence of Aortic and Ventricular Shear Stresses on the stiffness of Valve
Endothelial Cells
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Aortic valve endothelial cells (VECs) function in different heamodynamic
environments. The influence of shear stress patterns on the
biomechanical characteristics of VECs on each side of the valve has not
been investigated. We assessed the relative expression of actin
filaments and mechanical properties of VECs on intact porcine valve and
cultured VECs which were exposed to aortic and ventricular shear
stresses by a Cone-and-Plate machine. Immunofluorescent staining and
western blot analysis of actin filaments revealed a great expression in
VECs on the ventricular surface. Exposing the cells to the physiological
or reverse-side pattern of flow did not influence the heterogeneous
expression of actin on each side of the valve. By using the scanning ion
conductance microscopy, measurements of membrane compliance of
VECs demonstrated that VECs on the ventricular side (0.020±0.001
µm/kPa) were significantly stiffer than those on the aortic side
(0.032±0.002 µm/kPa). Moreover, the relative differences in the
mechanical properties of VEC on each side of the valve were not
affected by varying the pattern of shear stress exposed to the VEC on
either side of the valve. Under aortic and ventricular flow, membrane
compliances of VECs on the ventricular side were maintained at 0.0040.005µm/kPa, whereas those on the aortic side were retained at
0.011µm/kPa. This study has shown side-specific differences in the
biomechanics of VECs that is independent of the forces generated
across valve's surfaces. These findings further highlight the
heterogeneous nature of VEC and may have important implications
understanding how the valve functions in health and disease.
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Valve Interstitial Cell Remodeling Under Abnormal Mechanical Stress is
Mediated by 5HT and FGF2 Signaling
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Altered remodeling is often an early indicator of valvular heart disease,
however its link with valve mechanics or structure is not well understood.
Our previous work demonstrated that 5HTR2A and 5HTR2B expression
was upregulated when valve interstitial cells (VICs) experienced
elevated stress. Immunohistochemistry of normal and calcified human
valves showed that 5HTR2A, 5HTR2B and FGF2 were highly expressed in
calcified cusps, while FGF1 was expressed in normal cusps. Taken
together, we hypothesized that VICs respond to altered mechanical
stress by changing their matrix remodeling activities and that this
feedback is mediated via 5HT and FGF2 signaling in valve disease. In
the current study, we forced single VICs to self-assemble into rectangles
with 1:3, 1:5, 1:7 aspect ratio, to simulate 0%, 10%, 20% cyclic
mechanical loading, respectively. After 48 hours, immunofluorescence
showed strong expression of F-actin, FGF2, 5HTR2A, 5HTR2B, FGFR1
and FGFR2 at increased stretch. Interestingly, we observed the
localization of FGFR1 and 5HTR2A to actin cytoskeletal filaments while
FGF2 localized to microtubule structures. We will quantify gene and
protein expression in this model with the addition of serotonin and
different combination of receptor inhibitors. Valves in a mouse model for
hypertension and serotonin overload (3 weeks treatment) demonstrated
increased leaflet thickening and thickness of collagen fibers as
evidenced by picrosirius red staining. We expect our results to highlight
the interplay between FGF and 5HT signaling in the progression of
valvular heart disease and the key signaling molecules that can be
targeted for early identification and treatment of stress-mediated valve
disease.
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A synthetic scaffold for heart valve tissue engineering offers a high level
of reproducibility, low risk of infection and easy to tailored architecture
such as mechanical properties and porosity. However a purely synthetic
scaffold suffers a major drawback in that it offers little or no biomimictic
surface to direct cell adhesion, migration and function. Biomimitic
peptides are often simple, short peptide sequences that can exert
bioactivity. Through computer modelling we have designed and validate
different peptide amphiphiles (PA) tails that enhance coating ability of
the PA onto a synthetic polymer, poly ε-Caprolactone (PCL), which is
commonly used as a tissue engineered scaffold. The PA platform offers
a single polypeptide chain that contains both polymer anchoring site and
functional peptide region for a simple method to coat PCL scaffold with
specific bioactivity. In this study, we use collagen stimulating
peptide/peptide amphiphiles (PA) consisting of hydrophobic alkyl tails
and hydrophilic head that covalently bind to the hydrophilic active
peptide regions. Transmission scanning microscopy shows that the PA
are able to self assemble into nanofibers. Cell studies show that the PA
has low toxicity and enhances collagen production in adipose derived
stem cells between 6-13%. Further development of PA that confer
desirable cellular functions represents an exciting step toward the
construction of intelligent scaffolds suitable for a range of tissue
engineering applications including heart valves.
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Non-coaptation of tissue-engineered heart valves (TEHVs) is due to
cellular contractile forces and remodelling within the matrix, which act to
decrease the overall size of the leaflets. We propose to address this
problem by combining the advantages of fibrin gel as an autologous cell
carrier material with the contraction-buffering capability of a freeze-dried,
cross-linked collagen-glycosaminoglycan (CG) scaffold. The aim of the
present study was to assess the contraction of the CG-fibrin scaffold
(CGF) when seeded with human vascular smooth muscle cells (SMCs),
and to develop a tri-leaflet TEHV scaffold using the same material. Discshaped CG scaffolds (n=4) were cast and subsequently crosslinked
using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. Cells were seeded
into the scaffold at a density of 3,000cells/mm3 using a fibrin carrier
material. A control group consisted of cell-seeded fibrin without the CG
backbone material. After 7 days of culture, fibrin-only scaffolds
contracted to 10% of their original diameter, while the CGF scaffolds
maintained their original diameter. PicoGreen assay on the CGF scaffold
showed a significant increase in cell proliferation after 5 days, while livedead staining revealed few dead cells. Masson's trichrome staining
demonstrated that SMCs were homogenously distributed throughout the
CGF scaffold and that CG and fibrin were still present after 7 days.
Through the development of a mould and optimisation of freeze-drying
and infiltration parameters, a tri-leaflet TEHV CGF scaffold was
successfully produced. This CGF scaffold shows great potential for use
as a HV scaffold due to its ability to maintain structural integrity and
resist the contractile forces of seeded cells.
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Towards Designing Multifunctional Biomimetic Scaffolds for Tissue
Engineering Heart Valves
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Bio-mimetic peptides are extremely useful to decorate bio-signals and to
attract cardiac cells on scaffolds for tissue engineering (TE) heart valves.
However, customizing the bio-mimetic peptides for cardiac TE and
tailoring them to implant on the surface of the scaffolds require
understanding of their structural properties such as stability and selfassembly. Here, we use computational bioengineering to model biomimetic peptides with unique design for collagen stimulation in TE
construct and utilize molecular dynamics to study their structural
properties. The modeling results signify that the studied bio-mimetic
peptides form β-sheet for structural stability and self-assemble like
twisted ribbons, in which, it is interesting to see the arrangement of
collagen stimulation motifs as borders to attract cell receptors. The
potential bio-mimetic peptides models are synthesised to examine under
experimental conditions for ordered self-assembly, cell toxicity, collagen
production and coating on polycaprolactone scaffold. These ongoing
wet-lab experiments are essential to apply this novel design for TE heart
valves. The structural basis from this studywill be helpful to design a
multifunctional bio-mimetic scaffold for TE heart valves and to attract
different types of cells towards the scaffold.
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Scaffolding materials for tissue engineering should meet some basic
requirements, e.g. being degradable, support cellular adhesion and
provide adequate stimulation, i.e. growth factors (GFs). In this context
immobilized GFs bear great potential and GF-mimicking peptides would
be even more valuable. In this study we investigated the biological
performance of LL37 - originally described as an antimicrobial peptide as a VEGF-mimic.
LL37 was covalently grafted to a gold surface as a model substrate,
either directly or via polyethyleneglycol-mediated (PEG) coupling.
Proliferation of endothelial cells (ECs) was monitored using the Electric
Cell-substrate Impedance Sensing (ECIS) system, based on label-free
detection by resistance measurements.
PEG-immobilized LL37 was able to stimulate EC-proliferation over a
period of 72 h whereas directly coupled peptide showed no activity. The
mitogenic effect was comparable to soluble VEGF.
LL37 exhibits multiple biological functions of which the VEGF-mimicking
ability is currently under investigation. Conjugation of this peptide might
contribute to the vascularization problem of tissue engineering scaffolds
while circumventing the application of entire GF proteins. In this way
LL37 may add further biological features to cardiovascular tissue
engineering constructs.
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The aim of this study was the development and evaluation of a new cell
seeded bio-hybrid aortic valve scaffold based on human origin and
synthetic materials. Scaffolds (n=6) were manufactured using
decellularized homograft leaflets and polyurethane patches that were
sutured together on a conventional CoCr-Stent. Fibroblasts (FBs) and
endothelial cells (ECs) were isolated from saphenous vein segments
and expanded in culture. Scaffolds were seeded with FBs (7.5x105
cells/cm2), followed by static cultivation for 6 days. Subsequent ECseeding (7.5x105 cells/cm2) was realised under the same conditions.
Pre-conditioning was performed by an exposure to pulsatile low-flow
(750 ml/min) for 5 days in a standard incubator at 37°C and 5% CO2.
Implantation was simulated by crimping the valve with an available
crimping device followed by dilatation with a balloon catheter and finally
exposure to higher flow conditions (1500 ml/min) for 2 days. Valve
performance was documented by endoscopy. Samples were taken
before and after each processing step, and analysed by scanning
electron microscopy (SEM), immunohistochemical (IHC) and life-dead
staining. SEM evaluation and IHC staining against TE-7 (FB-specific)
and CD31 (EC-specific) proved the successful cell seeding process.
Establishment of an extracellular matrix was detected by staining against
collagen IV and fibronectin. The newly developed bio-hybrid scaffold
showed excellent performance under endoscopic visualization and
presented promising cell colonization characteristics, however, crimping
and balloon dilatation induced significant cell damages. In summary, it
seems that the crimping process has a big negative effect on biological
tissue and must therefore be critically evaluated in further research
studies.

47

C28
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Material Characterization And Prototype Realization
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Polymeric heart valves (PHVs) have been investigated since 1960 but
their success has been hampered by an overall lack of durability, due to
leaflets calcification and thromboembolic complications. The aim of this
work was to study a new elastomeric material for the development of a
single-body PHV.
CarboSil® (CS) was dissolved in THF/DMAc 1:1 (v/v) to obtain a 2%
(w/v) solution. CarboSil® solutions containing 10% (CS10) and 30% of
PDMS (CS30) were obtained by a reaction under stirring and nitrogen
flow for 6 h at 82 °C. For each materials planar patches were obtained
by a spray, phase-inversion technique on a rotating cylindrical mandrel.
In vitro tests were carried out to evaluate: bio/hemocompatibility,
calcification, hydrolytic degradation, oxidative degradation,
environmental stress cracking (ESC) degradation, and mechanical
properties.
Materials extracts showed no cytotoxic effects on mouse fibroblasts
respect to untreated cells. CS30 induced a lower in vitro platelets
adhesion than the CS one. Coagulation times were similar for all tested
materials. CS10 and CS30 showed less calcification spots compared to
CS (SEM). IR demonstrated no significant differences among CS, CS10
e CS30 samples after hydrolytic degradation. CS30 was less
susceptibility to oxidative degradation and to ESC. No mechanical
differences were found between all materials. A single-body PHV
prototype, with an incorporated stent, was successfully obtained by
spray, phase-inversion technique with CS30.
CarboSil®-PDMS processed by the spray material deposition on a 3D
mould, allowed the feasibility of a new low-cost and potentially long-term
performing PHV.
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Tissue-engineered heart valves that contain living cells are associated
with logistical hurdles. In contrast, decellularized xenografts and
allografts lack growth and remodeling capacity and either risk
immunogenic reactions and disease transmission or suffer from limited
availability. Therefore, we recently introduced decellularized tissueengineered heart valves (dTEHVs), based on biodegradable synthetic
materials and homologous cells, as an alternative off-the-shelf valve
replacement. Subsequently, we studied the functionality and host
repopulation capacity of such dTEHVs in non-human primate and ovine
models up to 24 weeks. Remarkably, the valve leaflets became rapidly
repopulated with endogenous cells, starting within 5 hours post-OP.
Excellent in-vivo performance of dTEHVs was demonstrated up to 8
weeks in the ovine model, where after mild to moderate insufficiency
developed. The small valvular insufficiency was also detected in the
non-human primates. Post-mortem the dTEHVs revealed mobile and
thin leaflets, however, relative leaflet shortening was observed in the
primates and beyond 8 weeks follow-up in sheep. Mechanical analyses
of the ovine leaflets showed a trend towards increased anisotropic
properties over time, resembling remodeling towards native-like valvular
properties. Remodeling was confirmed by increasing collagen density,
presence of elastic fibers, and endothelialized surfaces, starting in the
valvular wall, going into the leaflets over time. To overcome the
observed reduction in leaflet size, changes in valve geometry are
necessary in order to improve physiological loading of the leaflets.
Nevertheless, these homologous, non-immunogenic, off-the-shelf
dTEHVs with good initial valve performance, rapid cellular repopulation
and remodeling capacity have great potential as alternative to currently
used valve replacements.
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Currently used valvular prostheses lack growth potential. This is a major
problem for young children that need staged interventions to
accommodate growth of the valve with increasing risk of morbidity and
mortality.
Driessen-Mol et al.[1] demonstrated the unique regenerative capacity of
decellularized tissue-engineered heart valves (DTEHVs) in vivo. Proper
valve function was demonstrated up to 8 weeks, but was gradually lost
toward 24 weeks. Loss in valve functionality was observed in
accordance with increased host cell repopulation. Recent computational
simulations by Loerakker et al.[2] showed that when the current valve
geometry was subjected to hemodynamic loading, it resulted in radial
leaflet compression rather than the expected radial extension. Therefore,
we hypothesize that contractile host cell repopulation in combination with
hemodynamic leaflet compression, eventually may have resulted in
leaflet shortening and valve insufficiency.
Based on the computational results, the valve geometry was adjusted to
facilitate radial leaflet straining in diastole. Controlling DTEHV geometry
has been challenging so far, because tissue compaction during culture
always resulted in flattened leaflets. Therefore, a physical constraint was
introduced in the bioreactor system to enforce curvature of the leaflets.
During heart valve culture, cells compacted the leaflets around this
insert, which guided the valvular geometry while allowing nutrient and
oxygen supply to the valve. This resulted in excellent in vitro functionality
of the valves, matching the exact imposed geometry.
[1] Driessen-Mol et al., J Am Coll Cardiol., 2014
[2] Loerakker et al., Journal of Biomechanics, 2013
European Union's Seventh Framework Program: LifeValve (GA No.
242008).
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Clinically available tissue valves commonly employ the use of
chemically-fixed tissues that present minimal recellularization potential
and are prone to calcification. Utilizing an allogeneic, decellularized
engineered tissue valve could potentially satisfy these shortcomings by
enabling tissue maintenance and homeostasis due to their high
propensity for recellularization. We present here a novel tissueengineered heart valve design based on a collapsing tissue tube (Cox et
al, JTCS, 2005), using a decellularized engineered tissue tube.
Tissue tubes with strong circumferential alignment were grown by
fibroblast remodeling of fibrin gel over 5-7 weeks in vitro, including cyclic
distension conditioning to promote collagen transcription and deposition,
followed by decellularization. When such tubes grown from ovine
fibroblasts were implanted for 6 months as interpositional grafts in the
sheep femoral artery, they exhibited complete endothelialization and
recellularization with no dilatation, narrowing, mineralization, or immune
response.
When mounted on a custom frame (3-pronged crown), the tubular valves
made from 22 mm diameter ovine tissue tubes performed well in
pulmonary and aortic conditions of a pulse duplicator: >95% EOA, <5%
regurgitant fraction, <3 mmHg systolic pressure drop. Pre-clinical testing
of these valves is commencing. Performance of tubular valves made
from human fibroblast-derived tissue tubes is compared; like the ovine
tubes, the human tubes also possess mechanical strength / stiffness in
the 5 MPa range and mechanical anisotropy.
A frameless version of this tubular heart valve that has potential for
somatic growth and thus suitable for pediatric pulmonary applications is
also presented, including pulse duplicator studies.
Funding: NIH HL107572
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CorMatrix has designed a tricuspid valve from small intestine
submucosa (SIS) with the ability to remodel into patient tissue. This
design demonstrated excellent functional results two years post-implant
in an ovine model. An earlier feasibility study with 2-ply SIS yielded
better results with more rapid remodeling. Thus, the study objective was
to evaluate this valve design using different SIS configurations. Valve
function and remodeling were evaluated at three months (n=14). The
valve was sutured into a cylindrical sleeve (30mmX30mm). SIS
configurations included 2-ply, 2-ply pressed, and 4-ply. The native valve,
including chordae, was excised, distal end of the SIS valve sutured to
the papillary muscles, and proximal end sutured to the annulus.
Echocardiography and angiography evaluated in vivo valve function.
Histology included H&E, von Kossa, and Movat. Immunohistochemical
staining with Vimentin and SMA identified interstitial cells, and vWF and
eNOS identified endothelial cells. Echocardiography and angiography
showed complete coaptation of the leaflets with mild/no regurgitation.
Grossly, explanted valves appeared to be significantly remodeled at
three months. The 2-ply valves had consistent cellular infiltration and
confluent endothelial cell lining. The 4-ply valves contained microscopic
intracuspal thrombus and less consistent or less advanced cellular
infiltration. The 2-ply pressed configuration had excellent results in some
valves, but microscopic intracuspal thrombus in others. These results
demonstrate reproducible function of this valve design and influence of
SIS configuration on valve remodeling. The 2-ply valve, which
demonstrated excellent results in an earlier feasibility study, was
superior to the 4-ply and 2-ply pressed configurations.
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Historically, tissue-engineered heart valves (TEHVs) have been
designed to mimic the shape of the native valve to recreate the natural
haemodynamics. This implies the fabrication of leaflets to ensure the
unidirectional blood flow. However, the inadequate leaflets' functionality
ultimately determined the failure of TEHVs in preclinical studies. Here
we propose a tubular leaflet design as alternative to the classical design,
abandoning the idea of mimicking the complex native leaflets' shape.
Instead, a simple tubular tissue-engineered construct is sutured at three
distinct sinotubular commissural points and along a circumferential line
at the annulus level, so that it collapses inwardly and closes the conduit
when exposed to diastolic backflow. The valve can be either implanted
orthotopically in the aortic/pulmonary root by conventional surgical
replacement or it can be sewn into a self-expandable nitinol stent for
minimally invasive transcatheter delivery.
The valves were moulded in fibrin gel embedding human umbilical vein
cells and reinforced by a warp-knitted textile mesh for mechanical
stability. After three weeks of conditioning in bioreactors, the valves were
fully functional with unobstructed opening and complete closure. Tissue
analysis showed deposition of oriented collagen I and III and a confluent
endothelial cell layer on the surface of the valves. The valves underwent
crimping for 20 minutes to simulate the catheter based-delivery, with no
effect on their functionality, on the extracellular matrix organization nor
on the mechanical properties. These results show the potential of the
tubular leaflet design as an attractive alternative to the conventional
design of semilunar valve prostheses.
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Biological scaffolds have been assessed for tissue engineering
purposes, however the lack of long-term stability due to degradation in
some situations limits their use. Synthetic materials can overcome this
issue by offering longer stability with slower degrading rates. We have
previously developed a novel method to create synthetic anisotropic
fibers that can promote cell proliferation and matrix production. This
study aims to analyse the behaviour of the matrices in a dynamic
environment where pulsatile pressure is applied. Poly ε-Caprolactone
(PCL) aligned fibers made by using a jet spraying method were tested
with and without human mesenchymal stem cells (hMSCs) using a
pulsatile bioreactor. Aligned fibers are able to withstand pulsatile
pressure with a gradient of 0-80 mm Hg for up to 3 weeks without
ultrastructural damage as shown by scanning electron microscopy.
hMSCs were dynamically seeded for 7 days within the fibres to ensure
cell-spreading throughout the thickness as shown by DAPI staining of
transverse sections. The seeded scaffolds were then moved into a
bioreactor to test their durability. Pulsatile pressure was applied and
maintained at a gradient of 0-80 mm Hg for a further 7 days to mimic
aortic valve systemic conditions. Preliminary data show cells still present
inside the scaffold after exposure to pressure synthesized more collagen
than samples not exposed to pulsatile pressure. These results suggest
that under systemic pulsatile pressure, jet sprayed anisotropic PCL
fibres do not lose integrity and support cell function, proving to be good
candidate for further studies toward valve tissue engineered constructs.
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Previously, we demonstrated in vivo that ice-free cryopreservation (IFC)
reduced T cell infiltration heart valve leaflets compared with controls. We
hypothesized that IFC human tissues will exhibit reduced allogeneic
immune stimulatory properties compared with fresh untreated control
grafts. Human engineered blood vessels (TEBVs) were generated by
culturing smooth muscle cells on a polyglycolic acid scaffold,
cryopreserved with an 83% formulation (DMSO, propanediol and
formamide) and stored. Fresh and rewarmed, washed IFC TEBVs were
compared by incubation with human peripheral blood mononuclear cells
(hPBMCs) for 3 and 7 days. Proliferation was assessed by resazurin
assay and cytokines by ELISA. Statistical significance was determined
by t-test, p<0.05. There was no stimulation of hPBMC proliferation by
IFC TEBVs. Significant proliferation of hPBMCs occurred with fresh
TEBVs. Significantly lower IL-6, IFN-γ, TNF-α and IL-10 release from
IFC groups was observed compared with fresh tissue groups. IL-2, IL12, and IL-18 release were not in either IFC or control TEBV groups.
Additional culture controls with fresh and IFC tissues demonstrated that
cytokines were not detectable without the presence of PBMCs. We
conclude that ice-free cryopreservation of allogeneic TEBVs significantly
reduces the hPBMC proliferative response and cytokine release (IL-6,
IFN-γ, TNF-α and IL-10) compared with untreated, fresh TEBVs. The
source of cytokines was the PBMCs not the allograft tissues. These
results suggest that ice-free cryopreservation may be an improved
method for processing and cryopreservation of allogeneic human heart
valve and arterial tissues for surgical applications. Future studies will
compare IFC with decellularization methods. NIH Grant #R43EB014614
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It is not clear how tissue engineered materials for heart valvular
substitutes change in hitogenesis after implantation. We are developing
a novel autologous aortic valve (Biovalve), using simple, safe and
economical in-body tissue engineering which is based on a tissue
encapsulation phenomenon in the living body. In this study, we
investigated key factors in hitogenesis when the Biovalve was implanted
in a large animal model.
Biovalves were prepared by 2-month embedding of the plastic molds in
the subcutaneous spaces of goats. After extracting the molds and
removing the plastic rods only, Biovalves were constituted from
completely autologous connective tissues. We combined them with a
metaric stent and implanted in the aorta in situ with transcatheter valve
implantation technique.
The Biovalve Stents were successfully implanted in the aortic postion.
They were extracted 1, 2 or 5 months after implantation. The leaflets of
the Biovalve kept their shape and elasticity even after 5 months and
neither calcification nor thrombi were observed. Histological examination
showed the cell migration inside the Biovalves' body and laminar
endothelialization on the surface of the valve leaflets even in 1 month
after implantation. Their histogenesis have gradually advanced in 5
months, but were interrupted when the Biovalve tissues were not
attached enough on the native vascular wall tissue.
the Biovalve satisfied the higher requirements of systemic circulation in
goats for 5 months with the histogenic potential that was mainly induced
by cell migration from the native vascular tissues contacting with the
Biovalve.
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Dynamic Relationship between the Mitral Annulus and the Basal Left
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1
Linköping University, Linköping, Sweden, 2Stanford University, Palo Alto, CA,
USA
Mitral valve closure is preceded, during atrial systole, by reduced mitral
annular (MA) size. This reduction requires little inward force from
contracting atrial myocytes because the valve is open and left ventricular
pressure (LVP) is low. But this annular size reduction, important to valve
competence, is maintained by some inward-directed force during
ventricular systole and the source of this force is not well understood.
One possible candidate is contraction of the basal left ventricular
myocardium pressing inward on the annulus which requires tight
coupling between the MA and the basal LV myocardium. To test this
possibility, MAseptal-MAlateral and MAseptal-LVlateral dimensions were
computed from 4D marker data obtained every 16.7ms for 3 sequential
beats in each of 12 ovine hearts. The group mean Pearson Correlation
Coefficient between these dimensions for all data in all 12 hearts was
0.59 (range 0.04 to 0.80), thus the LV myocardium is not tightly coupled
to the MA. But basal LV dynamics did have a precise relationship to MA
dynamics. In late diastole, the MA moved inward while the LV base was
relatively fixed; in systole, the MA was relatively fixed, while the LV base
moved inward. During isovolumic relaxation, the MA moved outward as
LVP fell, while the LV base was relatively fixed. Thus the inward force
maintaining the annular size reduction is LVP acting on the posterior
leaflets; the LV pulls back, not presses in, on the annulus. Consideration
of this elegant mechanism may be important to the design of tissueengineered valves.
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Canonical and Non‐canonical TGFβ Inhibition Differentially Regulate Matrix
Homeostasis in Porcine Aortic Valve Interstitial Cells
Varun Krishnamurthy, Andrew Stout, Kristi Lim, David Allison, K. Jane Grande‐
Allen
Rice University, Houston, TX, USA
Misexpression of collagens and glycosaminoglycans (GAGs) is a
hallmark of aortic valve disease (AVD), and is frequently associated with
TGFβ pathway abnormalities. We investigated the effects of exogenous
TGFβ, pathway inhibition (Smad/canonical and ERK1/2/non-canonical),
aging, and stretch, on aortic valve interstitial cells (VICs) regulation of
ECM content and specifically, homeostasis of GAG hyaluronan (HA).
VIC cultures from suckling (1-3 month old) and aged (2 year old) pigs
were treated with TGFβ ± canonical (SB431542) and non-canonical
(U0126) pathway inhibitors for 48hrs, under 0% or 5% cyclic strain.
Secreted collagen, GAGs, and HA were quantified using
biochemical/electrophoresis assays. Expression of aSMA (VIC activation
marker) was assessed using RT-PCR. In suckling VICs, TGFβ elevated
GAG synthesis and reduced collagen synthesis. In aged VICs, both
collagen and GAGs increased with TGFβ addition in 0% and 5% strain
conditions. Both inhibitors rescued collagen levels but not GAG levels,
with or without TGFβ, for suckling VICs but not for aged VICs. TGFβ
activated suckling VICs; quiescence was partially restored with U0126,
but not SB431542. Neither inhibitor rescued cell phenotype for aged
VICs. TGFβ increased HA secretion 3-5X into culture medium and 10X
within the cell layer; SB431542 prevented HA retention in the cell layer
but HA secretion into the medium was unaffected. Results suggest
differential VIC regulation of ECM due to TGFβ and its inhibitors with
biomechanical stimulation. We speculate inhibition of ERK1/2 activation
reverses the defective regulation of valve ECM homeostasis, particularly
HA, early on, and reduces the potential for AVD later in life.
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We hypothesize that deriving the biomechanical state of AVICs in-situ
using an inverse modeling approach will reveal more accurate
information regarding AVIC adaptations to various stimuli. To achieve
this, a novel, integrated numerical/experimental methodology was
developed to estimate AVIC mechanobiological state in-situ. Flexural
deformations of intact AV leaflet specimens were used to quantify the
effects of AVIC stiffness and contraction at the tissue level. Next, we
incorporated tissue micromorphology in a down-scale framework that
simulates AVIC-Extracellular matrix (ECM) interactions as a function of
layer location. AVIC size, shape, distribution and orientation were
quantified from histological data from all three layers. A representative
volumetric element was optimized statistically for each layer to represent
the native 3D structure. The optimized RVE size in each layer defined a
single mesh element within the macro model. Cellular inclusions and
surrounding ECM were defined as neo-Hookean materials. Experimental
flexure data from three different activation states (thapsigargin, basal
tonus and hypertensive) were used in conjunction with the model to
probe the effects of AVIC stiffness and contraction on the tissue level
response. The computed differences between the computed macro and
micro stress was attributed to cell stiffness and contractile changes. This
numerical/experimental methodology was be used to deduce AVIC
properties under various pathophysiological conditions. We are currently
using the desired approach to the effects of statins.
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Heart valve disease is a major cause of mortality and morbidity in the
Western population. More than 25% above the age of 65 suffers from a
form of heart valve disease. The only current therapy is the replacement
of the diseased valve with a prosthetic valve. Little is known about the
cellular and molecular mechanisms underlying the initiation and
progression of heart valve disease. This is mainly due to the absence of
a heart valve disease model, which allows manipulation of the
environmental conditions of the valve in its normal position in the heart.
We have adapted the existing Minitiature Tissue Culture System (Lieber
et al., 2010) and created culture conditions supporting the initiation and
progression of heart valve disease in the mouse aortic and mitral valve.
Thickening of the leaflets, proliferation and activation of the valvular
interstitial cells, disruption of the extracellular matrix organization are
observed. In addition, we have findings that suggest the endothelial to
mesenchymal transformation of the endothelial cells of the valves. This
model allows the modification of the hemodynamic, chemical and
metabolic conditions, which are main determinants of the valvular
organization, and therefore, could provide major insights in the
mechanisms underlying heart valve disease.
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Bicuspid aortic valve (BAV) is often complicated by thoracic aortic
dilation. Since aortic diameter as a criterium for surgery is only decisive
at population level, it would be valuable to have tailored risk stratification
at patient level. Therefore, we investigated structural differences
between the aortic wall of BAV and tricuspid aortic valve (TAV) and
identified immunohistochemical markers predictive of aorta dilation in
BAV.
Biopsies of the ascending aorta of BAV (n=36) and TAV (n=23) both
without (BA, TA) and with (BAD, TAD) dilation were compared.
Differentiating and mature vascular smooth muscle cells, lamin A/C, and
progerin were studied immunohistochemically and with western blot.
Further an activation cascade was investigated, featuring c-Kit,
phosphorylated c-Kit (pc-Kit), mmp9, Hif1alpha and eNOS ,to unravel
possible differences within the BA group.
BAVs showed significantly less expression of differentiated smooth
muscle cells: αSMA, SM22α, calponin and smoothelin as compared to
TAVs. Lamin A/C and progerin expression was significantly lower in BAV
than TAV (p<0.05). Progerin expression increased significantly in TAD
as compared to TA. The activation cascade with pc-Kit as a keyfactor,
was present both in a subset of patients with BA and BAD.
Our study showed that the aortic wall with BAV is less well differentiated
as compared to TAV. Phosphorylation of c-Kit plays a crucial role in
aortic dilation in BAV rather than inflammation and accelerated aging
seen in TAV. For the first time, a subgroup is distinguished in BAV
patients without aorta dilation suggestive of a different state of
vulnerability for future aortopathy.
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Second Harmonic Generation Microscopy For Analysis Of Collagen Fiber
Alterations In Calcific Aortic Valve Disease
Heather Hutson, Kristyn Masters
University of Wisconsin, Madison, Wisconsin, USA
Extracellular matrix (ECM) remodeling is one of the earliest hallmarks in
the development of calcific aortic valve disease (CAVD). However,
traditional histochemical analysis does not provide information about
higher-order ECM structure, such as collagen fiber organization.
Characterizing the dynamic behavior of these structures is important for
not only understanding disease-related changes in valve architecture
and its impact on valve mechanics, but also for potentially developing
imaging approaches that allow earlier CAVD detection. We performed
confocal second harmonic generation microscopy (SHG) on aortic
valves from healthy and diseased humans and found numerous changes
in collagen fiber architecture that were visible using SHG but not
detectable via histochemistry. In contrast to the collagen-sparse
spongiosa in healthy valves, diseased valves possessed randomlyaligned collagen fibers throughout the leaflet mid-section, with a sudden
transition to tightly and uniformly aligned collagen fibers in the fibrosa.
Despite similar density, the fiber directionality in the diseased fibrosa
was substantially different from that in the healthy fibrosa. Analysis of
forward-scatter SHG intensities, forward/backward scatter ratio, and
Monte Carlo modeling of the SHG data revealed additional differences in
collagen fiber density, length, diameter, and crimping at different disease
stages. Interestingly, there was low standard deviation of collagen
organization patterns within both the healthy and diseased valve groups,
which was unexpected given the heterogeneity of CAVD. This study
advances our understanding of ECM remodeling in CAVD, and may
provide a basis for use of SHG in the detection or evaluation of CAVD
progression utilizing real-time in vivo SHG techniques.
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Dezellularized valve allografts re-endothelialized with autologous
endothelial cells (EC) from vessels or differentiated from peripheral
blood have shown promising results. To circumvent this invasive,
respectively, low-success harvest of EC, we utilized autologous umbilical
cord blood EPC derived EC for re-endothelialization of ovine
decellularized pulmonary valves (UCBEC-DPV) and compared them to
those re-endothelialized with peripheral blood derived EC (PBEC-DPV).
UCBEC-DPV and PBEC-DPV (n=6, each) were implanted orthotopically
in sheep (Ø 72 kg, age 2 y). Umbilical cord blood was kept frozen until
EPC isolation for re-endothelialization. Valve function was investigated
at implantation and at explantation 8 months post OP by
echocardiography. Cusps´ surface cell coverage was analysed by
phalloidin stain. Cellular repopulation and matrix integrity was analysed
by histological stainings, while the identity of cells in the matrix was
characterized by immunological staining.
One animal (UCBEC-DPV) did not recover from anaesthesia. No valve
related problems occurred during implantation period. Valves exhibited
no insufficiencies, cusps were thin and translucent at explantation time.
Cusp surfaces showed no significant difference concerning cell
coverage among groups. In both groups matrix repopulation was mainly
limited to ventricular sides of cusps and to adventitial sides of valvular
walls. Cells covering cusps revealed expression of vWF, eNOS, sm-αactin and sm heavy chain 2.
Re-endothelialization with ECs from both sources showed to be equally
beneficial for function and repopulation of valves with host cells. As no
cell type revealed to be superior, cell source could be chosen
individually from case to case.
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Expression and activity of extracellular ectoenzymes (CD39 and CD73) in
aortic valves cells and in endothelial cells under the shear stress conditions.
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Extracellular nucleotides have major impact on thrombosis, inflammation
and immune responses, but their expression and activity is valve is
poorly studied. Normal aortic valves and calcified valves were analyzed
for ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto5'-nucleotidase (CD73) gene expression and immunocytochemical
localisation. Nucleotide metabolism was characterised by incubation with
AMP and ATP in both cultured human aortic valve endothelial (VECs)
and interstitial cells (VICs). In addition, the influence of ventricular and
aortic side flow patterns on CD39 and CD73 was assessed. CD39 was
highly expressed in VECs and VICs with reduced levels of expression in
calcified valves. In contrast CD73 was more highly expressed in calcified
regions of the valves. When the VECs were exposed to their
physiological pattern of flow the activity of CD39 and CD73 increased
significantly (p<0.05). In conclusion, ventricular and aortic flow could
play an important role in ectoenzyme expression in endothelial cells. The
presence of CD39 and CD73 in valves suggests that valve have the
ability to degrade extracellular nucleotides, which may contribute to the
protective effect of their degradation product adenosine against
inflammation and calcification.
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An increasing number of young patients are choosing bioprostheses for
aortic valve replacement. In this context the Ross operation deserves
renewed consideration as an alternative biological substitute.
Reoperation rates after the Ross procedure and after bioprosthetic AVR,
however remain a concern in these patients.
We report freedom from reoperation after the Ross procedure and
bioprostheses for different age groups.
The reoperation rates of 1.925 patients (mean age 41.2 ± 15.3 years,
1.444 male) from the German Ross registry with a mean follow-up of 7.4
± 4.7 years (range 0.00 - 18.51 years, 12866.6 patient years) were
analyzed and compared to bioprostheses in three age groups (Group I <
40 years, Group II 40-60 years, Group III > 60 years).
At 10 (resp. 15) years of follow-up freedom from reoperation was as
follows: Ross Group I 83% (85%), Ross group II 90% (90%) and Ross
group III 81% (81%). Bioprostheses had the following results: Group I
51% (35%), Group II 63% (25%) and Group III 92% (81%).
There is some evidence that at least in the first 10 and 15 years after
aortic valve replacement the Ross procedure provides a lower
reoperation rate in younger and middle-aged patients compared to
patients with bioprostheses. This may be of interest to patients' or
physicians' for decision making for aortic valve surgery.
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Should Cryopreservation Be Abandoned?
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Evaluate the mid-term clinical and echocardiographic results of fresh
decellularized versus cryopreserved decellularized pulmonary allografts
for RVOT during the Ross operation.
Between 2005 and 2013, 166 Ross operations were performed using
SDS decellularized pulmonary valve allografts. Of these, 124 were fresh
decellularized allografts (mean age = 30±15 years) (Group 1) and 42
were cryopreserved decellularized allografts (mean age= 34±11 years)
(Group 2). Conduit dysfunction was defined as any peak gradient > 40
mmHg or insufficiency grade III or IV. Comparisons were made with
Kaplan Meier survival estimate and the mean of peak gradients over
time by the unbalanced two way repeated measures ANOVA.
Peak gradients at hospital discharge (Group 1 = 14±5 mmHg and Group
2 = 10±5mmHg) and at the latest follow-up (Group 1 = 14±5 mmHg and
Group 2= 17±13 mmHg) were similar between groups (p=0,78). Peak
gradient >40mmHg was never present in Group 1 but in 3 patients in
Group 2. Moderate or severe regurgitation was present in one case of
each group. Freedom from conduit dysfunction at 6 years was
significantly better in Group 1 (97% - CL95%, 85-99%) versus Group 2
(85% - CL95%, 78-90%) (p=0,014) at six years. Reoperation due to SVD
was needed in only one patient in Group 2.
Fresh decellularized allografts were associated with better medium term
results when compared to cryopreserved decellularized allografts for
RVOT reconstruction up to six years of follow-up. These results indicate
that cryopreservation is unnecessary and may be even detrimental
during the processing of decellularized allografts.
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Hans‐Hinrich Sievers1, Ulrich Stierle1, Marc Albert2, Ulrich Franke2, Armin
Gorski3, Efstratios Charitos1, Roland Hetzer4, Jürgen Hörer5, Rüdiger Lange5,
Anton Moritz6, Arlindo Riso7, Jörg Sachweh7, Wolfgang Hemmer8
1
University of Lübeck, Lübeck, Germany, 2Robert‐Bosch‐Hospital, Stuttgart,
Germany, 3University of Würzburg, Würzburg, Germany, 4German Heart Center,
Berlin, Germany, 5German Heart Center, Munich, Germany, 6University Clinic of
Frankfurt am Main, Frankfurt am Main, Germany, 7University of Hamburg,
Hamburg, Germany, 8Sana Heart Surgery, Stuttgart, Germany
Conventional aortic valve replacement(AVR) in the young, active patient
represents a suboptimal solution, in terms of long term survival and
quality of life. Aim of the present work is to present our multicenter
results with the pulmonary autograft in young patient undergoing aortic
valve replacement.
Between 1992-2013, 1967 patients (1786 adults;41.6±15.1 years)
underwentAVR with the pulmonary autograft principle in 9 centers. All
patients underwent prospective clinical and echocardiographic
examinations, annually. Mean follow-up was 7.7±4.8 years (range 0-23)
with a total cumulative follow-up of 14571 years with 635 patients having
a follow-up of at least 10 years.
In-hospital mortality was 1.37%(n=26). Late survival of the adult
population was comparable to the age and gender matched general
population (observed deaths:90, expected deaths:70; p=0.439).
Freedom from autograft reoperation at 5, 10, and 15 years was 97.8%,
95.9% and 89.6% respectively whereas freedom from homograft
reoperation was 98.4%, 96.6% and 94.6% respectively. Overall freedom
from reoperation was 96.2%, 92.8% and 86.2% respectively.
Longitudinal modeling of functional valve characteristics revealed a
low(<5%) probability of a patient being in higher autograft regurgitation
grades throughout the first decade.
For the young, active patient requiring aortic valve replacement, the
autograft principle results in postoperative long-term survival comparable
to that of the age and gender matched general population and
reoperation rates within the 1% / patient*year boundaries. The autograft
principle for the treatment of the aortic valve disease in young, active
patients who want to avoid the shortcomings of conventional prostheses
should be strongly considered.
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There is continuing concern about the risk of long-term autograft
dilatation following the Ross procedure. The objective of this study was
to characterise the shape and function of neo-aortic root both in dilated
and nondilated states.
Among 108 Ross patients undergoing yearly echocardiographic
assessment in our unit for 16.5 ± 1.9 years after operation (range 13 20), 11 patients with dilated autografts (DG, >45mm, age 47 ± 10) and
10 patients with non-dilated autografts (NDG, <45mm, age 59 ± 7) were
consented for cardiac multi-slice cine CT. Dimensions and distensibility
of the aortic root were derived from the cine-CT images, and were
compared with 11 age-matched normal controls (age 47 ± 9). The aortic
valve function was also analysed by echocardiography.
Additionally to the difference in the sinus diameters between DG, NDG
and C (50 ± 3 mm vs 41 ± 3 mm vs 31 ± 4 mm, p < 0.01), the noncoronary sinus of the DG tended to have larger height than that of NDG
and C groups. DG patients had similar distensibility compared to control
(25 ± 14 vs 34 ± 14 MPa-1, p = 0.20) whereas NDG patients showed
trend towards lower distensibility (13 ± 7 MPa-1). Echocardiographic
data showed only 2 severe and 2 moderate regurgitations, with no clear
correlation between regurgitation severity and sinus dimension.
These data support the notion that the autograft root has similar physical
properties to the normal aortic root despite significant dilation, which was
reflected in its haemodynamic function.
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Infundibular stenosis occurring in “tetralogy of Fallot” has been found to
be a very challenging abnormality to repair. We replaced the pulmonary
valve with a combination of decellularized allogenic valve together with
autologous vascularized matrix (= AutoVaM) as patch material to
enlarge the RVOT.
RVOT reconstruction was performed in minipigs. A decellularized
allogeneic valve conduit was used in place of the pulmonary valve and
AutoVaM obtained from the small intestine with preserved vessels as a
patch to enlarge the outflow tract. Control animals received nonvascularized autologous pericardium instead. Valve function was
analysed by MRI. At explantation 3 and 6 months post OP, phalloidin
was used to visualize cell coverage on the cusp surface. Repopulation
and ECM integrity were examined by histological stainings and cell
identity by immunofluorescence stainings.
Allograft developed more severe insufficiencies when combined with a
pericardial patch as observed by MRI. The cell layer on the cusp did not
cover more than ¼ of the ventricular surface at explantation. Matrixrepopulation with cells was moderate in the valvular wall and minimal in
the cusps´ base. Cells between valvular wall and cusps consisted of
cells positive for vimentin and sm α-actin. Clusters of smooth muscle
cells (sm α-actin and MYH11 positive) were still detectable 6 months
post OP within AutoVaM patches but never in pericardial patches. Few
Troponin-T-positive cells were found in the patches towards the
ventricular anastomosis.
Clinical outcome and MRI analysis showed a better outcome of valve
and heart function when allogeneic valves were combined with
AutoVaM.
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Young women wishing to become pregnant are choosing Ross operation
for aortic valve replacement as an alternative to mechanical or biological
substitute. But there are limited data on maternal and perinatal outcome
of pregnancy.
We report outcome of pregnancy after the Ross procedure.
42 Pregnancies among 31 women (mean age at Ross operation
25.0±6.1 years) with a mean follow-up of 10.5±4.8 years (range 2.5 22.4 years, no lost of FU, no death) were analyzed.
24 women gave birth to one child, 5 women to two, one woman to three
and one woman to four children. One baby was a stillbirth. There have
been five reoperations in three women (four homografts for SVD, one
autograft for NSVD in combination with one homograft for SVD). Two out
of these five reoperations have been after the birth of a child in two
women due to SVD of the homograft in one patient and due to one
autograft for NSVD in combination with one homograft for SVD in the
other patient. Three reoperations have been in one patient before
childbearing due to SVD of the homograft three times. In last FU after
birth there has been non aortic valve-regurgitation or pulmonary valve
regurgitation > II° in all women.
Ross procedure seems to be a possibility for uncomplicated and
successful pregnancy in women with aortic valve disease.
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Valve-sparing aortic root prostheses with anatomically shaped sinuses
(“sinus prosthesis”, Uni-Graft® W SINUS, Braun) imply nearphysiological conditions. Therefore, we sought to test their
hemodynamics in comparison to straight grafts and volunteers by use of
4D flow MRI. Scans of 16 patients after David operation (13 sinus
prostheses: “SP”, 1f, 54±14y; 3 straight grafts: “SG”, 1f, 51±13y) and 13
age-matched healthy volunteers (“Vol”, 11f, 55±6y) were examined at 3T
(Philips Achieva) after written informed consent. Using GTFlow
(GyroTools, CH) data were visualized with streamlines and particle
traces. Occurrence and magnitude of secondary flow patterns (vortices,
helices) in the thoracic aorta and its sinuses were graded and correlated
with aortic geometry.
Whereas sinus vortices in SP resembled those of Vol, SG revealed
abnormally formed vortices aligned orthogonal to the vessel wall. Sinus
vortices were graded small or medium in 91% (SP) and 98% (Vol)
analysis of 6 datasets ongoing due to aliasing; In SG, 22% showed no
sinus vortex, 78% only small vortices. Patients revealed more aortic
secondary flow patterns than Vol (SP: 2.6±0.8, SG: 3.0±1.0, Vol:
1.4±0.8; p<0.05), potentially due to steeper postoperative curvature
angle. Round aortic arch configuration predominated in Vol (11/13)
compared to cubic (SP: 8/13, SG: 2/3) and gothic (SP: 3/13; SG: 1/3)
forms in patients.
Near-physiological sinus flows in sinus prostheses is reassuring. The
increased number of secondary flow patterns distal to prostheses,
however, is hemodynamically of concern and should trigger follow-up
studies and the discussion, whether curved grafts could mitigate those
clearly abnormal blood flow patterns.
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Aortic Valve Dynamics After Valve‐sparing Procedure With The New ‘Sinus’
Prosthesis Used For Valve Sparing Aortic Root Replacement
Claudia Schmidtke, Hans‐H. Sievers
Klinik für Herz‐ und thorakale Gefässchirurgie, Universitätsklinikum SH, Campus
Lübeck, Lübeck, Germany
Durability of aortic valve sparing root reconstruction depends on root
dimensions and leaflet stress. A new “Sinus prosthesis” imitates the
anatomical root considerations (Unigraft® W SINUS,B. Braun
Melsungen AG,Germany). Aim of this study is the evaluation of aortic
valve hemodynamics after valve sparing root reconstruction with this
prosthesis.
In the first 38 patients (32 m/6 f; mean age 52±13.1 years; range 24-70
years) who underwent valve sparing procedures (02/2009-04/2012)
according to the David reimplantation technique using the new Sinus
prosthesis (SP),aortic valve movement was examined
echocardiographically and compared to 20 healthy controls (C). Opening
and closing motion patterns as well as distensibility of the aortic root and
function of the valve were studied.
Aortic valve opening and closing characteristics were as follows: rapid
valve opening velocity was comparable between groups (SP: 40.9±9.1
vs. C: 36.8±21.9 cm/s;p=0.24), rapid valve closing velocity was faster in
SP than in controls (26.4±11.0 vs. 14.6±13.9 cm/s;p=0.002). Percent
change of diameter,as a parameter of distensibility,was comparable to
controls at the level of annulus and sinutubular junction and lower at
sinus level (3.2±2.7 vs. 4.7±2.6%,p=0.048).
The new sinus prosthesis imitates the native sinuses with normal
dimensions of the sinuses.Closing velocity of the cusps is faster after SP
implantation than in native roots of controls. Distensibility is limited
according to the material.The dynamic behavior of the AV after root
reconstruction with the SP is not completely physiological
yet.However,mid-term results of valve function are suitable.The aim
should be the development of a more elastic material for this prosthesis.
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In Vitro Analysis of The Alterations Produced by Transcatheter Aortic Valve in
The Valsalva Sinuses
Andrea Ducci, Francesco Pirisi, Spyridon Tzamtzis, Gaetano Burriesci
University College London, London, UK
Transcatheter Aortic Valve Implantation (TAVI) has rapidly become the
preferred solution for high-risk patients. However, despite the excellent
short and medium term results, this approach has recently been
associated with high rates of ischemic lesions and dementia. In most
cases, these cannot be directly correlated with catheter manipulation
during implantation, or with the severity of calcification. Hence, the
source of the complications is reasonably to be sought in the flow
perturbations produced by transcatheter valves. In fact, contrary to
surgical solutions, TAVI devices are positioned inside the leaflets of the
diseased valve, which are widened into the sinuses of Valsalva,
producing alterations of the phyisiological hemodynamics.
In this work, in order to gain a better understanding of the fluid dynamic
perturbations introduced by transcatheter valves, particle image
velocimetry was used to measure the flow in a mock aortic root made of
transparent silicone. To isolate the effects of transcatheter valves, the
operating valve was encased in a transparent cylindrical wall, mimicking
the expanded native leaflets after TAVI. The experiments were carried
out in a pulse duplicator, under physiological conditions, using a fluid
solution providing optimum refractive index matching with the root and
dynamic viscosity similar to blood.
Direct comparison of the mean flow dynamics indicated that TAVI
produces stagnation regions at the bottom of the Valsalva sinuses,
which may promote thrombus formation and contribute to ischemic
lesions. The study also provides accurate estimates of local shear and
dissipative rates and turbulence levels, that are typically associated to
blood damage.
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Aortic valve replacement with decellularized aortic allografts: First clinical
results
Igor Tudorache, Anatol Ciubotaru, Thomas Breymann, Samir Sarikouch,
Dietmar Boethig, Alexander Horke, Luitgard Meschenmoser, Serhhei Cebotari,
Axel Haverich
Medizinische Hochschule Hannover, Hannover, Germany
The use of decellularized valved allografts shows promising results in
replacement of the pulmonary valve. Here, we report about our clinical
results of aortic valve replacement using decellularized aortic
homografts (DAH) in children and adults.From February 2008 to
February 2014, 34 patients with a mean age of 23 years (range, 0.19 to
65) were prospectively assessed after aortic valve replacement using
DAH. Mean time from homograft harvesting to implantation of DAH was
46 days (range, 25 to 69). The mean DAH diameter was 23 mm (range,
10 to 27). Mean extracorporeal circulation and aortic cross-clamp time
was 211 and 120 minutes respectively (range, 113 to 397 and 64 to 180)
using DAH for aortic root replacement, including coronary transfer.
There was one early, none conduit related, death (3,5%).
Echocardiography and magnetic resonance imaging were used for
postoperative evaluation. None of the patients required re-intervention or
conduit explantation so far. In two patients (7.41%) a moderate aortic
valve insufficiency was seen, no severe valve stenosis was observed so
far. No dilatation of the aortic root was seen, however the follow up is
short so far (45 years in total, mean 1.5 yrs., max. 6 yrs). DAHs satisfy
the requirements of the systemic circulation. For selected patients, DAH
may represent an interesting alternative to conventional other grafts.
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Patient‐Specific Finite Element Modeling of Ascending Thoracic Aortic
Aneurysm Using In Vivo Magnetic Resonance Imaging
Liang Ge, Michael Hope, David Saloner, Andrew Wisneski, Kapil Krishnan, Julius
Guccione, Elaine Tseng
University of California San Francisco Medical Center, San Francisco, CA, USA
Elective ascending thoracic aneurysm (aTAA) repair is based on family
history, connective tissue disorder, growth rate, but primarily size.
Rupture/dissection carries a high mortality and occurs in many patients
who had not met size criteria for surgical repair. Wall stress may be
better predictor than size for adverse events, but cannot be directly
measured in vivo, rather determined from finite element analyses (FEA).
Current FEA models are fraught with assumptions that limit result
accuracy. The purpose of this study was to develop the first patientspecific aTAA model using in vivo magnetic resonance imaging (MRI) to
assess wall thickness, material properties, and 3D-geometry. ATAA
patient underwent 4D-flow DENSE MRI. Lumen geometry and wall
thickness were used to create surface contour meshes of aTAA
geometry. DENSE measured circumferential and longitudinal aortic wall
strain and wall material property was derived using inverse analysis.
Zero-stress geometry was derived using a novel fast pre-stress
approach. Peak von Mises stress of FEA model with zero-pressure
correction was 465kPa, while without zero-pressure correction the model
predicted 272kPa. Average von Mises stress predicted by zero-pressure
correction FEA model was 98±18kPa while that for non-zero-pressure
correction was 86±16kPa. ATAA models in literature have not accounted
for zero-stress configuration or patient-specific material property. We
demonstrate that in vivo MRI can be used to obtain patient-specific
parameters that significantly impact wall stress results. Future
computational models that use wall stress to predict aTAA adverse
events must take into account zero-stress geometry and patient material
property for accurate wall stress determination.
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P1
Chondrogenic Pathways Involved In The Development of Myxomatous Valve
Disease
Alexia Hulin1, Jonathan Cheek1, Christina Alfieri1, Robert Hinton1, Alain Colige2,
Katherine Yutzey1
1
The Heart Institute, Cincinnati Children's Hospital, Cincinnati, Ohio, USA,
2
GIGA, Laboratory of Connective Tissues Biology, Sart‐Tilman, Belgium
Myxomatous mitral valve (MMV) prolapse is the second most common
heart valve disease and the leading cause of mitral regurgitation. The
hallmark of myxomatous disease is an excessive accumulation of
proteoglycans leading to thickened heart valve leaflets. Moreover, focal
areas, which display chondrogenic features, are observed indicating that
myxomatous disease processes mimic chondrogenesis. However, the
underlying molecular mechanisms driving chondrogenic gene
expression in diseased valves are still poorly understood. Therefore, two
murine models with skeletal defects were examined as potential models
of myxomatous disease. Osteogenesis imperfecta murine (Oim) mice
have a spontaneous mutation in Collagen1a2 leading to altered collagen
content and structure. Adult homozygous mice display thickened aortic
valves primarily due to increased proteoglycan deposition as indicated
by pentachrome staining. Sox9, Collagen 2 and Hapln1 also are
increased. Similarly, mice deficient in Axin2, a negative regulator of
Wnt/β-catenin signaling, also develop thickened proteoglycan-rich aortic
valves with increased chondrogenic markers, including increased
aggrecan expression. These markers are consistent with chondrogenic
features observed in myxomatous area of human MMV. Interestingly,
chondrogenic differentiation appears to occur also in MMV from patients
with Marfan syndrome and in the Fbn1C1039G mouse model for Marfan
Syndrome. Together these mouse models indicate that chondrogenic
pathways are active in myxomatous disease and can be used for future
mechanistic studies of MMV progression and prevention.
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P2
Versican Is Markedly Elevated During The Early Pathogenesis Of Murine
Aortic Valve Disease
Mark Blaser1, Jung‐Woo Kwon1, Kuiru Wei1, Yu‐Qing Zhou2, Mark Henkelman2,
Craig Simmons1 ,3
1
Institute of Biomaterials and Biomedical Engineering, University of Toronto,
Toronto, Ontario, Canada, 2Mouse Imaging Centre, Toronto Centre for
Phenogenomics, Toronto, Ontario, Canada, 3Department of Mechanical and
Industrial Engineering, University of Toronto, Toronto, Ontario, Canada
The initial pathogenesis of aortic valve disease is poorly understood.
Proteoglycans are putative early therapeutic targets, as they mediate
initiation of atherogenesis and surround calcified valvular nodules. We
examined the impact of a mildly atherogenic diet on proteoglycan
content/composition in the mouse aortic valve.
Male C57Bl/6J wild-type mice were fed control or high-fat (HF) diets for 4
or 16 months. Valve function was assessed by echocardiography, and
matrix composition/morphology by (immuno)histochemistry. Cultured
porcine aortic VICs were treated with/without 5 ng/ml TGF-β1 for 5 days.
At 4 months, valve function was unchanged between diets (p = 0.75),
and all leaflets were negative for αSMA, CD45, and ApoB. HF leaflets
were distally thickened (+126%, p < 0.05) due to proteoglycan
deposition (+110%, p < 0.01), not collagen accumulation (p = 0.87). Only
versican was elevated in HF leaflets (+138%, p < 0.05), with no change
in decorin (p = 0.69) or biglycan (p = 0.59). Differential proteoglycan
expression was mirrored in culture: TGF-β1 elevated total proteoglycan
synthesis (+114%, p < 0.05), but only versican mRNA was increased
(+53%, p < 0.05) while decorin and biglycan were reduced (-105% and 162% respectively, p < 0.01). By 16 months, HF mice developed
impaired valve function with increased transvalvular velocity (+48%, p <
0.05). HF leaflets were proteoglycan-rich, αSMA-positive, and fibrotic,
with all leaflet regions (proximal/medial/distal) thickened vs. controls
(+493%, +472%, +77% respectively, p < 0.001).
Thus, diet-induced valve dysfunction is preceded in mice by early
versican synthesis that leads to leaflet thickening and fibrosis.
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Non‐Linear Optical Visualisation Technologies For Characterisation Of Aortic
Valve Sclerosis In A Murine Model
Anett Jannasch1, Saskia Faak1, Christian Schnabel2, Roberta Galli2, Edmund
Koch2, Klaus Matschke1, Thomas Waldow1
1
Department of Cardiac Surgery, Faculty of Medicine, TU Dresden, Herzzentrum
Dresden, Dresden, Germany, 2Institute of clinical Sensoring and Monitoring,
Faculty of Medicine, TU Dresden, Dresden, Germany
Degenerative heart valve disease like aortic valve stenosis (AVS) is
characterized by disorganization of fibers in the extracellular matrix and
cell invasion. Currently most histological-based methods for
characterization of AVS demand for extensive processing of extracted
valve material with impact on tissue morphology. We present a novel
approach combining coherent anti-Stokes Raman scattering (CARS),
endogenous two-photon excited fluorescence (TPEF) and second
harmonic generation (SHG) to characterize AVS on aortic leaflets from
apoe-/- and wildtype mice. In addition optical coherence tomography
(OCT) enables thickness measurements and 3D visualization of murine
aortic valve leaflets dynamics. OCT demonstrated increased leaflet
thickening from 30µm up to 80µm, aortic valve insufficiency and
decreased opening angle in apoe-/- mice. TPEF illustrated decreased
and fragmented elastin fibers (ventricularis), SHG showed increased and
disorganized collagen fibers (fibrosa) and CARS displayed adipocytes
infiltration in apoe-/- whereas the wildtype did not show any of those
pathological changes.
Using non-linear optical microscopy cusp constituents can be examined
simultaneously, three-dimensionally and without extensive manipulation
of the sample. These technologies using high resolution imaging
methods require no staining procedures, enable the analysis of the
progression of AVS and give impressive insights into a complex disease.
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Patient‐Specific Fluid Structure Interaction Simulation of Ascending Thoracic
Aortic Aneurysm Using In Vivo Magnetic Resonance Imaging
Liang Ge1 ,2, Henrik Haraldsson1, David Saloner1 ,2, Michael Hope1 ,2, Elaine
Tseng1 ,2
1
University of California San Francisco, CA, USA, 2San Francisco VA Medical
Center, San Francisco, CA, USA
Elective ascending thoracic aneurysm (aTAA) repair is based on family
history, connective tissue disorder, growth rate, but primarily size.
Rupture/dissection carries a high mortality and occurs in many patients
who had not met size criteria for surgical repair. Wall stress may be a
better predictor than size for adverse events, but cannot be directly
measured in vivo, rather determined from finite element analyses (FEA).
FEA analysis of aortic stress faces many unique challenges. Reference
(unloaded) geometry of aortic wall can't be readily measured; in vivo wall
material property is often unknown. In this work we implement novel
techniques to address these challenges. 4D flow MRI imaging was used
to measure patient specific aortic blood flow information and
displacement encoding with stimulated echo (DENSE) MRI was used to
measure cyclic aortic wall motion. Aortic lumen geometry was contoured
from MRI images and was used to create a numerical model of the
aTAA. DENSE measured wall motion was used in an inverse analysis to
characterize aortic material property. Reference geometry of the aortic
was derived using a novel pre-stress approach. These patient specific
aortic wall characteristics were then used to conduct a fluid structure
interaction (FSI) simulation to calculate the in vivo wall stress. In vivo
blood flow conditions measured from the 4D MRI were used as inlet
boundary condition. We achieved unprecedented level of patient
specificity in terms of in vivo aneurysm wall stress prediction. Further
work on validation could pave the way for clinical applications of aTAA
wall stress analysis.
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Tissue‐Engineered Textile‐Reinforced Mitral Valve ‐ Second Generation TexMi
Ricardo Moreira1, Valentine N. Gesché 2, Luis G. Hurtado‐Aguilar1, Nuno Alves1,
Thomas Schmitz‐Rode1, Julia Frese1, Stefan Jockenhoevel1 ,2, Petra Mela1
1
Department of Tissue Engineering & Textile Implants, AME‐Hemholtz Institute
for Biomedical Engineering, RWTH Aachen, Aachen, Germany, 2Institut für
Textiltechnik, RWTH Aachen, Aachen, Germany
Tissue engineering a complete mitral valve substitute is challenging
because of the anatomical complexity of the native valve and the high
load conditions it has to withstand. Recently we realised the proof-ofprinciple of the first tissue-engineered, fibrin-based, textile-reinforced
mitral valve - TexMi - recapitulating the main anatomical features of the
native valve i.e. the annulus, the asymmetric leaflets and the chordae
tendineae, a crucial element to preserve the ventricular pumping
efficiency which is, however, disregarded in the commercial available
(non-viable) substitutes. The TexMi valve relies on a hybrid scaffold
consisting of fibrin gel as a cell carrier and a warp-knitted mesh that
defines the 3D geometry and provides mechanical stability. Here we
present the second generation of the TexMi, with a load-optimised textile
co-scaffold and improved design with four fully tissue-engineered
chordae tendineae to be sutured at the papillary muscles. The valves
were moulded with human cells isolated from the vein of the umbilical
cord and cultivated under dynamic conditions over three weeks.
Immunohistochemical staining showed the presence of aligned collagen
fibres which appear striated in transmission electron microscopy. The
collagen content was approximately 50% of the content found in the
native mitral valve and the burst pressure reached 1000 mmHg. The
considerable extracellular matrix formation and the high burst strength
are encouraging results towards the realisation of a living prosthesis
specifically designed for implantation in the mitral position.
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Novel CALP Pericardium Shows Superior Hydrodynamics and Fluid Structure
Interaction Compared to Current Bioprosthetic Valve Tissues: A Computer
Simulation
Yaghoub Dabiri1, Todd J Anderson1, John V Tyberg1, Janet Ronsky2, Imtiaz Ali1,
Michael Wong1, Kishan Narine1
1
University of Calgary Libin Cardiovascular Institute of Alberta, Calgary,
Canada, 2University of Calgary Schulich School of Engineering, Calgary, Canada
We developed a novel pericardial based tissue (CALP) for bioprosthetic
and tissue engineered heart valves. The influence of its material
properties on blood flow, as well as its fluid structure interaction when
fixed and decellularized for bioprosthetic valve manufacture were
numerically simulated. Glutaraldehyde fixed and decellularized CALP
was compared to that of Glutaraldehyde (Glu) fixed and decellularized
bovine pericardium (BP) and porcine (PV) heart valve leaflets. Tissues
were fixed in 0.6% Glu and stored in 0.2% Glu for testing. A twodimensional fluid structure interaction was modeled using Comsol
Multiphysics finite element package (version 4.4, Comsol Ltd., London,
UK). Calculated values for Young's modulus from uniaxial tests were:
10, 8, 8 and 5 MPa for fixed PV, BP and CALP and decellularized CALP,
respectively. The calculated Young's modulus of decellularized BP and
PV was close to their fixed samples (approximately 8 and 10 MPa), and
hence, simulations were not performed for these samples. Maximum
valve opening was calculated as 82.26,74.52,71.13% of annulus
diameter, for decellularized and fixed CALP and fixed PV, respectively.
The time of maximum valve opening was similar (13.17,13.01,13.02%
cardiac cycle). The peak pressure gradient was 0.49,0.51 and 0.53kPa,
and peak Von Mises stress was 0.47,0.68 and 0.78MPa, for
decellularized and fixed CALP and fixed PV, respectively. Peak shear
rate was 21.13,18.68 and 16.67×1031/s. CALP could be considered as a
superior alternative for valve fabrication as fixed CALP opening and
structural behavior were similar to BP and decellularized CALP showed
superior structural and opening behaviors compared to other materials.
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Characterization and Validation of a 3D PEG‐NB Screening Platform for
Improved MSC‐Based Heart Valve Tissue Engineering
Jenna Usprech1, Craig Simmons1 ,2
1
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Canada, 2Mechanical and Industrial Engineering, Toronto, Ontario, Canada
Substrate properties (physical and biochemical) as well as external
mechanical and soluble chemical cues are important
microenvironmental factors for directing the differentiation of bone
marrow mesenchymal stromal cells (bmMSCs) in vitro. Select
combinations of these factors have been applied to bmMSCs (mostly in
2D) for the purpose of heart valve tissue engineering. However, the
integration of environmental factors in 3D culture has yet to be
appropriately considered, despite being necessary for functional valve
tissue development. To address this, we sought to characterize and
validate a 3D screening platform that enabled the combinatorial
assessment of chemical and stiffness factors affecting bmMSC viability,
morphology and differentiation to a valve phenotype. Human bmMSCs,
encapsulated in 4 –11 wt% (5–30 kPa) polyethylene glycol norbornene
(PEG-NB) hydrogels, were cultured for 1 week. Viability and
morphology of bmMSCs were assessed as a function of polymer wt%
and RGD concentration. Factorial central composite designs modeled
the viability and morphology responses, demonstrating an optimal wt%
and RGD concentration for maximal viability and spread
morphology. Separately, the effect of polymer wt% on the promotion of
a synthetic valve phenotype (indicated by enhanced α-SMA staining)
was investigated by supplementing media with 5 ng/mL TGF-β1 for 1
week. The intensity of α-SMA staining significantly increased 1.6 fold in
response to TGF-β1 treatment in both 4.7 and 7.5 wt% PEG-NB gels,
but remained constant for 10.3% gels. This study highlights a novel
platform with which to identify specific aspects of the 3D valve
environment that direct bmMSCs to produce valve tissue.
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Assessment of Parylene C Thin Films for Heart Valve Tissue Engineering
Isra Marei1 ,2, Adrian Chester1, Themistoklis Prodromakis3, Tatiana Trantidou3,
Magdi H. Yacoub1
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of Biomedical Engineering, Imperial College London, London, UK
Scaffolds are main components of the proposed model of the tissue
engineered heart valve (TEHV), which provide mechanical support, and
guide cell growth and tissue formation. Thus, we investigated the
compatibility of parylene C (PC) for use as scaffolds in TEHV by
studying its biocompatibility and mechanical properties. Plasma oxidized
PC slides were coated with type I collagen or fibronectin, and their
adsorption was estimated by protein staining. To investigate the
compatibility of PC with valve cells, porcine pulmonary valve endothelial
and interstitial cells were grown on plasma oxidized PC with different
types of ECM coating and their adhesion, viability, apoptosis, and
phenotype were determined. Also, the mechanical properties of PC were
measured and compared to porcine aortic valve, and the effect of film
thickness on the mechanical properties was studied. PC showed
compatibility with protein adsorption, and valve endothelial and
interstitial viability and phenotypic expression. In addition, PC exhibits
high yield strength and ultimate tensile strength, indicating its high
resistant to fracture and plastic deformation. All of these properties
indicate that PC could be suitable for use as scaffold for tissue
engineered heart valves. The high stiffness of this material could be a
drawback, so PC should be tailored to reduce the stiffness.
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Surface Functionalization Of Anisotropic Nanofibers For Driving Human
Mesenchymal Stem Cell Behaviour
Ivan Carubelli1, Jerome Sohier2, Ann McCormack1, Padmini Sarathchandra1,
Adrian Chester1, Magdi Yacoub1
1
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Synthetic scaffolds for tissue engineering have proven to be good
alternative to biological ones due to their flexibility in the manufacturing
process and their controllable biodegradability. However, they lack
biological cues for improved cell adhesion, migration and function. Poly
ε-Caprolactone (PCL) films and aligned PCL fibers were coated with
Dendri-Graft Poly-L-Lysine (DGL) and RGD peptide to investigate the
effect on human mesenchymal stem cells migration and
proliferation. Films and aligned fibers were coated with DGL-bound
RGD peptide and compared with uncoated scaffolds. Cells were
incubated for 15 minutes or 2 hours, stained with DAPI and phalloidin to
quantify cell numbers and cell adhesion by means of total cell area. After
15 minutes incubation cell adhesion was higher when the DGL was
bound to RGD peptide compared to both uncoated scaffolds or DGL
only coated. This difference was even greater after 2 hours. Using
specially designed chamber slides, a cell free area was created on
surface of PCL fibers to study cell migration. Preliminary results show
that even in a 3D structure the DGL-RGD coating improves cell
migration by a faster cell growth/migration rate toward closing the gap
compared to uncoated fibers. The use of DGL and extracellular matrix
mimicking peptides such as RGD, could prove to be a good strategy to
increase cell adhesion and induce specific cellular response on a
synthetic scaffolds.

84

P10
PNGase F removes glycocalyx structures of decellularized porcine pulmonary
heart valve matrices
Katja Findeisen, Axel Haverich, Andres Hilfiker
MHH; LEBAO, Hannover, Germany
Implantation of xenografts leads to graft rejections. So far the αGal
epitope was identified as strongest xenoantigen present on non-human
grafts. Carbohydrates in general are believed to be xenoantigens, since
the glycocalyx is species-specific. To address and circumvent the limited
availability of human decellularized heart valve matrices for heart valve
replacements in future, we investigated the removal of glycocalyx
structures of porcine pulmonary heart valves (PPHV) by decellularization
and glycolytic treatment.
PPHV were decellularized by different detergent-based protocols and
enzymatically treated by PNGase F. Potential carbohydrate removal was
investigated by histochemistry using isolectin B4 (IL-B4) staining αGal
epitops, wheat germ agglutinin (WGA) staining N-acetylglucosamines,
datura stramonium lectin (DSL) staining β- 1,4 linked Nacetylglucosamines and N-acetyllactosamines, and ricinus communis
agglutinin I (RCA I) staining N-glycosides. Samples decellularized only
served as controls.
All lectins stained native PPHV, whereas a reduced lectin stain was
observed on decellularized PPHV matrices in dependence of the
decellularization protocol used. Compared to native tissue,
SDS/TritonX100 reduced IL- B4 but not WGA, DSL, or RCA I. The other
protocols reduced IL-B4, WGA and DSL stains. PNGase F abolished ILB4, WGA, and DSL stains independent on the type of decellularization.
Thus, decellularization per se reduced αGal whereas decellularization by
SDS/Na-deoxycholate and TritonX100+SDS, but not by
SDS/TritonX100, additionally led to a removal of N-acetylglucosamines.
Cleavage of GlcNacβ(1-N)Asn sites by PNGase F eliminates detergentindependent carbohydrate structures like αGal and Nacetylglucosamines. In summary, detergent based decellularization
followed by PNGase F treatment resembles an efficient way to remove
potentially immunogenic epitopes from PPHV.
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BMP‐pSmad1/5/8 Pathway Activation in a Novel Mouse Model of Calcific
Aortic Valve Disease
M. Vicky Gomez1 ,2, Jonathan D. Cheek1, Elaine E. Wirrig1, Katherine E. Yutzey1 ,2
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Calcific Aortic Valve Disease (CAVD) affects >2% of the population over
the age of 65, for whom the only clinical therapy available is valve
replacement surgery. Furthermore, the underlying pathogenic
mechanisms of CAVD, which could serve as potential therapeutic
targets, remain unknown. Klotho-null mice exhibit accelerated aging and
aortic valve calcification similar to human CAVD. Notably,
phosphorylation of Smads1/5/8, Bone Morphogenetic Protein (BMP)
pathway effectors essential for bone calcification, is detected prior to the
onset of calcification and later localizes with calcified nodules in Klothonull aortic valves. Our hypothesis is that activation of the BMPpSmad1/5/8 signaling cascade promotes aortic valve calcification in
CAVD. Our preliminary studies demonstrate that osteo-chondrogenic
factors are significantly increased in Klotho-null aortic valves, and
pSmad1/5/8 activation precedes their induction in the region of the valve
where calcification occurs. Moreover, increased BMP2/4 ligand
expression is detected prior to, as well as during, calcific nodule
formation. Together these data support an active role for BMP signaling
as a critical mechanism in the development of CAVD. Our ongoing work
includes: 1) Identifying the requirements for the BMP pathway in aortic
valve calcification in vitro, and 2) Determining if BMP pathway inhibition
can prevent or inhibit aortic valve calcification in vivo.

86

P12
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Phenotype In Aged Mice
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Calcific aortic valve disease is paradoxically correlated with osteoporosis
in humans. Hyperlipidemia has been independently linked to both of
these pathologies, and may represent a unifying causative factor
between these two conditions. We examined this relationship by feeding
male C57Bl/6J wild-type mice a control or a high fat (HF) diet (58.7%
kcal from fat, cholesterol < 0.1% w/w) for 16 months ad libitum.
Echocardiography was used to examine valve function, and blood
testing determined serum cholesterol levels. Mouse bone mineral
density (BMD) was measured using a Piximus bone density scanner.
Overall weight of the HF group was 45% (p < 0.001) higher than the
control, indicating obesity, and corresponded with elevated non-HDL
cholesterol levels (+62%, p < 0.05). This coincided with the onset of
valvular dysfunction, with a 48% increase in transvalvular velocity (p <
0.05). The BMD of mice on the HF diet was reduced in the femur,
humerus, and whole skeleton by 7-16% (p < 0.05 vs. control diet). Bone
mineral content in HF mice was also reduced 23-24% from controls (p <
0.001). The whole-body and femoral BMD was inversely correlated (r2 =
0.43 - 0.49, p < 0.01) with transvalvular velocities in all mice. Overall, our
results support the notion that mild hyperlipidemia leads to both valve
dysfunction and altered bone metabolism in obese mice. Further
investigation of the paradoxical progression of cardiovascular disease
with osteoporosis under hypercholesterolemic conditions should be
considered when examining long-term mouse models of valve disease.
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Relationship Between Free Aldehyde Groups In Bioprosthetic Heart Valves
And Calcification
Tara Tod, Jeff Dove
Edwards Lifesciences, Irvine, Ca, USA
Glutaraldehyde is commonly used to crosslink the collagenous matrix of
pericardium leading to increased durability and reduced antigenicity of
bioprosthetic heart valves. Structural valve deterioration due to
calcification is the primary failure mode in these valves. Calcification is
believed to be caused by multiple factors with glutaraldehyde as one of
the major factors. Anti-calcification technologies have been developed to
address this specific factor, yet the mechanism is still not completely
understood.
The objective of this work is to describe the amount of free aldehyde
groups in glutaraldehyde-fixed bovine pericardium used for bioprosthetic
heart valves and how it relates to in vivo interactions such as
calcification. The concentrations of residual aldehyde groups found in
bovine pericardium were determined by a novel test
method. Glutaraldehyde fixed tissue contained a high amount of free
aldehyde groups, while tissue produced using GLX, an advanced
integrity preservation technology which permanently caps residual
aldehydes, contained an 88% reduction in aldehyde values. Calcification
studies showed significantly higher calcification in tissue containing high
concentrations of aldehyde residuals compared to low aldehyde
residuals, with a 99.4% reduction in calcium for GLX tissue. The
relationship between aldehyde levels and calcification potential of
bioprosthetic tissue may be used as a tool for explaining the mechanism
of calcification due to glutaraldehyde of bioprosthetic heart valves.
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Investigating the Potential of Valve Interstitial Cells to Act in a Perictye
Manner by Promoting Angiogensis and Invasion by Valve Endothelial Cells
Christopher Arevalos, Kathryn Grande‐Allen
Rice University, Houston, TX, USA
Calcific aortic valve disease (CAVD) is the third leading cause of heart
disease in adults. It has been hypothesized that therapeutically stopping
the formation of microvessels during early CAVD could prevent the
pathological progression of the disease. However, the lack of
understanding of valve cellular pathology has stymied discovery of
potential treatments. Pericytes have been localized histologically along
the exterior of these microvessels, but it is unknown whether these cells
are derived from valve interstitial cells (VICs) or if VICs can differentiate
into a proangiogenic pericyte phenotype. Therefore this study
investigated the perivascular potential of VICs to stabilize valve
endothelial cell (VEC) angiogenesis in a matrigel model and investigated
potential VEC/VIC signaling pathways controlling their organization
using small molecule inhibitors. Control vascular derived endothelial and
pericyte cell lines formed stabilized networks in the model, but valve
interstial cells collapsed valve endothelial cell network formation over 24
hours into spheroids. Interestingly after spheroid formation, VICs began
to promote valve endothelial cell sprouting into the matrix and were
found wrapped around the VECs. These behaviors are suggesting both
a pericyte-like and invasive phenotype for the VICs. This process was
found to be Rho Kinase, protein kinase C, TGF-B, and Tie2 dependent
and to be VEGF, NOTCH, NO, and PDGF independent at the
concentrations tested in this study. The results of this study align with
current hypothesises of the pathology of CAVD and offer new insights
into the VEC/VIC dynamics during its progression.
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MG53‐Mediated Protection in Heart Valve Biology
T.M. Ayodele Adesanya1, Hua Zhu1, Tao Tan1, Ki Ho Park1, Joy Lincoln2 ,1, Jianjie
Ma1
1
The Ohio State University, Columbus, Ohio, USA, 2Nationwide Children's
Hospital, Columbus, Ohio, USA
Utilizing both overexpression and extracellular application, we aim to
target MG53, an essential cell membrane repair protein, to valvular cells
for treatment of tissue injuries associated with valvular heart disease
(VHD). Our group has identified MG53 as an essential component of the
cell membrane repair machinery. Membrane repair is important to
maintain normal cellular physiology, and disruption of this process can
result in disease in a number of different tissues. With the four heart
valves experiencing a tremendous amount of mechanical stress, we
have utilized microelectrode needle penetration and glass bead damage
assays to assess the ability of MG53 to protect valvular interstitial cells
from physical injury. Furthermore, we have begun calcification studies to
investigate the ability of MG53 to protect against inflammatory and
osteogenic changes associated with VHD. To date, we have observed
MG53-mediated protection against membrane damage through both live
cell imaging and LDH release. With preliminary results, we have also
noted MG53-mediated protection against changes in osteogenic gene
expression after LPS treatment. Ongoing tests will further characterize
the mechanisms of protection in valvular cells and assess the effects of
MG53 in in vivo models of VHD. We anticipate that, once all of our aims
are completed, our experiments will greatly contribute to the study of cell
biology, regenerative medicine, and cardiovascular disease, the number
one cause of death in the United States and worldwide.
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Relevance of YAP/TAZ Transcriptional Co‐factors on Mechanotransduction of
Aortic Valvular Interstitial Cells
Claudia Dittfeld, Wolfgang Witt, Anett Jannasch, Janin Andres, Maria Feilmeier,
Klaus Matschke, Thomas Waldow
Medical Faculty, TU Dresden, Dresden, Germany
Activity and nuclear vs. cytoplasm localization of the transcriptional cofactors YAP (Yes-associated protein) and TAZ (PDZ-binding motive,
WWTR1) have recently been associated to ECM stiffness e.g. in
mammary epithelial cells, mesenchymal stem cells and cancer cells.
Therefore these factors may represent key mediators of cell
differentiation in response to ECM elasticity and cell shape. Accordingly,
it has been presented that activity and localization of YAP/TAZ was
under control of RhoA and the functional state of the actin cytoskeleton
independent of Hippo kinases. Since mechanical cues reportedly affect
structure and function of aortic valves this study aims at potential roles of
YAP and TAZ as mediators of mechanotransduction.
The expression of YAP/TAZ was analyzed in valvular interstitial cells
(VIC) and quantified after culturing on soft gels with different stiffnesses.
The total expression level of YAP and TAZ protein was elevated when
VICs were cultured on surfaces with an elastic modulus of 25 kPa
reflecting the matrix stiffness in fibrotic valves. On soft gels reflecting the
stiffness of healthy valves (8 kPa) the protein expression was
significantly lower.
Whereas the localisation was not clearly correlated to matrix stiffness
immunofluorescence experiments revealed a partially co-localisation of
YAP to fokal adhesion kinase on collagen coated stiff matrices.
Aims of the project are now to investigate signaling cascades of cellmatrix interaction and/or stress fiber formation in relation to YAP as well
as TAZ expression and localisation in VICs to define the relevance of
YAP/TAZ in mechanotransduction and osteoblastic differentiation of
aortic VICs.
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An In Vitro Model for the Investigation of Potential Mechanical Interactions
Between Surgical Sealants and Aortic Tissue
Stacy Arnold1, David Gale1, David Hollinworth1, Davide Pacini2
1
CryoLife, Kennesaw, GA, USA, 2University of Bologna, Bologna, Italy
BioGlue® Surgical Adhesive is approved for use in cardiac, vascular, and
pulmonary surgery, as an adjunct to standard methods of repair (such as
sutures, staples, electrocautery, and/or patches) to bond, seal, and/or
reinforce soft tissue. This study evaluated the potential mechanical
effects of BioGlue when applied to reinforce a suture line surgical repair
of a valved aortic conduit.
A defect was created in six aortic conduits, each conduit being bisected
by a single incision just above the sinus. A 4-0 Prolene running suture
line was then used to reattach the two halves of the conduit. BioGlue
was applied to the suture line of three conduits. The remaining three
conduits did not receive BioGlue.
The physiological motion of the conduit was simulated using a Dynatek
Heart Valve Tester. All conduits were loaded into the tester and cycled
at approximately 200 cycles per minute with a closure load of 100
mmHg.
Daily inspections were performed to assess any changes to the surgical
repair of each conduit. Visual examinations show the suture underneath
the regions where the BioGlue had been applied to remain intact and in
its original condition. There was no impact on suture performance as a
result of BioGlue application over 60 million cycles. The suture material
and tissue showed no signs of dehiscence, suture fracture, fraying,
tearing, or abnormality. The study will continue to run to a target of 120
million cycles.
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Optimization Of Cyclic Stretching For Acceleration Of Collagen Production In
Fibrin‐Based Engineered Tissue Equivalents
Robert Tranquillo, Jill Schmidt
Univ. of Minnesota, Minneapolis, MN, USA
Fibrin is a promising scaffold material for tissue engineered heart valves,
as it is completely biological, allows for engineered matrix alignment,
and is able to be degraded and replaced with collagen by entrapped
cells. However, the initial fibrin matrix is mechanically weak, and
extensive in vitro culture is required to create valves with sufficient
mechanical strength and stiffness for in vivo function. Cyclic stretching
has been shown to increase collagen production by cells entrapped in a
fibrin scaffold, accelerating the strengthening of the tissue and reducing
the required culture time. However, the entrapped cells adapt to
constant amplitude cyclic stretching, suggesting that some perturbation
to a constant amplitude regimen may maximize the benefit.1-3 In this
study, intermittent cyclic stretching (alternating stretching and rest) and
incrementally increasing strain amplitude cyclic stretching were explored
to overcome this adaptation and accelerate collagen production. Using a
Flexcell Tension System, the effects of constant amplitude, intermittent,
and incrementally increasing amplitude cyclic stretching regimens were
investigated for neonatal human dermal fibroblasts entrapped in a fibrin
scaffold. The cellular response was studied at the signaling level by
monitoring the extracellular regulated kinase (ERK) and p38 pathways
and at the gene transcription level by monitoring collagen transcription.
Total collagen content and tensile properties of the resulting tissues
were quantified. Collagen production was accelerated using an
optimized cyclic stretching regimen.
Funding: NSF Graduate Research Fellowship and NIH/NHLBI
HL107572.
1

Paxton JZ, Tissue Eng. Part A 2012, 18(3-4):277-84.
Rubbens MP, Tissue Eng. Part A 2009, 15(5):999-1008.
3
Syedain ZH, PNAS 2008, 105(18):6537-42.
2
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Parameter Estimation of Heart Valve Leaflet Hyperelastic Mechanical
Behavior Using An Inverse Modeling Approach
Ankush Aggarwal, Michael S. Sacks
Center for Cardiovascular Simulation Institute of Computational Engineering
and Sciences Department of Biomedical Engineering, Austin, USA
In this work, we present a method for determining the functional
properties of heart valve leaflets from non-invasive imaging techniques
such as ultrasound and CT. The novelty of present approach is the use
of collagen fiber maps to constrain the optimization and the use of a
coupled surface fitting/in-plane strain approach to obtain new information
for structural modeling of valve leaflets. As a first step, we use in-vitro
experimental data from porcine bioprosthetic heart valve emulating an
aortic valve put in a flow loop. The leaflet was imaged at three different
static transvalvular pressures of 40, 80 and 120mm Hg using surface
markers and dual-camera setup. This highly comprehensive data set
with high resolution, marker positions at multiple pressures, valve
specific fiber architecture and biaxial data was ideal for this study – to
design the inverse model, validate it and calculate it’s sensitivity to
various input parameters and optimization constraints. This information
when combined with the inverse model presented in this work will lead to
an in-vivo assessment tool for heart valves and help diagnose problems
in the mechanical functionality at an early stage. Additionally, this
approach will have the potential to serve as a general-purpose in-vivo
assessment tool for heart valves – for evaluating the performance of
replaced prosthetic valves as well as monitoring the progression of valve
diseases.
Acknowledgements: NIH R01 Grants HL108330.
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A Computational Framework for Multiscale Modeling of the Mitral Valve
Chung‐Hao Lee, Michael S. Sacks
Center for Cardiovascular Simulation Institute of Computational Engineering
and Sciences Department of Biomedical Engineering University of Texas at
Austin, Austin, USA
The mitral valve (MV) is one of the four heart valves which locates in
between the left atrium and left ventricle and regulates the unidirectional
blood flow and normal functioning of the heart during cardiac cycles.
High-fidelity computer simulations provide a means to connect the
cellular function with the organ-level MV tissue mechanical responses,
and to help the design of optimal MV repair strategy. We present here
the details of our first steps to create state-of-the-art of mitral valve
modeling techniques, with an emphasis on what is known and
investigated at various length scales. A modified left heart simulator was
used for acquisition of the in-vitro mitral valve deformations at stress-free
(referential), pressure loaded (~30 mmHg) and fully loaded (~70 mmHg)
states. The segmented MV geometry at each state was imported into
Geomagic Studio for generation of the corresponding finite element
model. The 3D locations of the key points for representation of the MV
chordae tendineae, such as MV PM attaching points, chordal branching
points, and MV leaflet attaching points, were quantified for realistic
reconstruction of chordae tendineae (297 three-dimensional truss
elements). Moreover, spatially-varied and anatomically accurate MV
leaflet thicknesses were determined from the Micro-CT data. Next,
collagen fiber micro-structural information was mapped onto the finite
element model. The numerical predictions of the deformed geometry
agreed well with the in-vitro experimental data, with the total
displacement errors. We thus conclude that the improved accuracy of
the current mapping techniques do indeed provide more accurate
modeling results of the MV.
ACKNOWLEDGMENTS This research was supported by NIH grant R01
HL-089750.
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A novel experimental/numerical method to assess BHV biomaterial fatigue
response in‐vivo
Kristen R. Feaver1, Will Zhang1, Hobey Tam2, Jeremy R. McGarvey3, Norihiro
Kondo3, Robert C. Gorman3, Joseph H. Gorman3, Narendra Vyavahare2, Michael
S. Sacks1
1
University of Texas at Austin, Austin, USA, 2University of Clemson, Clemson,
USA, 3University of Pennsylvania, Philadelphia, USA
There does not currently exist a means to evaluate and predict in vivo
bioprosthetic valve response to long-term cyclic loading and blood
contact interactions. Herein, we present a novel, integrated
numerical/experimental technique to assess BHV biomaterial response
in vivo in a completely device independent manner. GLUT treated
porcine aortic valve leaflets are cut into shape and implanted in the
anterior mitral valve leaflet of Dorset sheep. To explore the stress
induced change in configuration, we implanted the PAV patch in 2
different orientations: with the circumferential direction of the patch
aligned to the circumferential direction of the mitral valve (C-C aligned),
and with the circumferential direction of the patch aligned to the radial of
the mitral valve (C-R aligned) thus interchanging the loading boundary
condition in the circumferential and radial direction of the patch. To
quantify the in vivo deformation and subsequently determine the in vivo
stress, 4 sonocrystals are placed at the corners of the implanted patch,
with an additional one at the center. An inverse finite element model is
applied to the implanted patch using shell elements. After four weeks in
vivo, the tissue was explanted and further evaluated for mechanics and
microstructure. Results demonstrate that when compared with the
original cross-linked material, the patch implanted in the C-C orientation
exhibited a nearly identical stress-strain response when subjected to
biaxial mechanical testing. However, the patch implanted in the rotated
C-R orientation was drastically increase in stiffness and exhibit
significant permanent creep along the radial direction of the patch.
Acknowledgements: NIH R01 Grants HL119297, HL108330,
HL073021, HL063964.
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Adipose‐Derived Stem Cells as a Potential Source of Valve Endothelial Cells
Napachanok Mongkoldhumrongkul1, Magdi Yacoub1 ,2, Adrian Chester1 ,2
1
Imperial College London, London, UK, 2Qatar Cardiovascular Research Centre,
Doha, Qatar
Valve endothelial cells (VECs) have been demonstrated to have a role in
the regulation of the mechanical and biological integrity of the valve. As
part of tissue engineering of heart valve, endothelial cell (EC) source is
required that will match VECs in terms of the ability to respond to the
flow patterns found on the aortic and ventricular surface of the valve.
This study focuses on using adipose-derived stem cells (ADSCs) as a
potential source of VECs and differentiating them into side-specific
VECs by aortic and ventricular shear stress patterns. After stimulation
with endothelial media, VEGF and side specific shear stress, ADSCs
were positively stained for CD31, vWF and NOS III, and exhibited the
ability to take-up low-density lipoprotein. Semi-quantitative analysis of
the level of the staining demonstrated that the aortic shear stress
significantly increased the expression of NOS III (10.25 fold) and SMαA,
(6.52 fold) as compared to the static control, whereas the ventricular
shear pattern does not induce the same effects (n=3). These studies
reveal that ADSCs have the potential to differentiate into VECs.
Moreover the finding that the different flow patterns induce the different
expression of the EC marker suggests the importance of specific flow
pattern on the differentiation of ADSC-derived VECs. Further function of
ADSC-derived VECs to communicate and regulate VICs will be
investigated.
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A New Strategy for Heart Valve Decellularization for Tissue Engineering
Jessica Boldt, Georg Lutter, Beke Sarrahs, Jan Schoettler, Jochen Cremer, Anja
Metzner
University hospital Schleswig‐Holstein, Campus Kiel, Department of
Cardiovascular Surgery, Kiel, Germany
Tissue engineering of pulmonary heart valves represents an enormous
advantage for the treatment of Tetralogy of Fallot. It is important to find
out the best decellularization method to preserve native structure of the
leaflets before seeding with autologous cells.
Porcine pulmonary heart valves were prepared and decellularized
enzymatically. Six heart valves were treated with Trypsin/EDTA for 12
hours (group 1) and six heart valves with AccutaseTM for 96 hours (group
2). Heart valves were embedded in paraffin, analyzed histologically
using H.E.-, Movat- pentachrome-, Elastica/van Gieson- and immunohistochemistry-staining using anti-collagen I and III.
Movat-Pentachrome- and Elastica/van Gieson-staining demonstrated
complete collagen structure in group 2 whereas in group 1 collagen
structure was diffuse and not completely preserved. H.E.-staining
showed remaining cell nuclei in group 1 revealing an incomplete
decellularization. In contrast, group 2 revealed no cell nuclei. AccutaseTM
incubation time was tested at different time points and demonstrated no
cell nuclei and prevention of the structure after 96 hours whereas
Trypsin/EDTA did not reveal complete structure after 12 hours. The
collagen structure analyzed using anti-collagen I and III- staining
indicated in group 1 destroyed cellular structure whereas in group 2
various cell structures were completely preserved.
In this study we demonstrated that AccutaseTM did not degrade the
original structure of the leaflet while the original cells were completely
removed. The rest of the DNA, we have found, will be analyzed by a
cooperation group (Prof. Kaatsch, UKSH, Campus Kiel, Institute of
forensic medicine).
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Adipose Tissue‐Derived Stem Cell Sourcing for Heart Valve Tissue
Regeneration; Selection of the Optimal Anatomical Site and Harvesting
Procedure in Sheep
Marius Harpa1, Terezia Preda1, Ionela Movileanu1, Ovidiu Cotoi1 ,2, Dan
Simionescu1 ,2
1
University of Medicine and Pharmacy, Tirgu Mures, Romania, 2Clemson
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The isolation and cultivation of stem cells from experimental animals has
become a common research technique in the field of regenerative
medicine. The aim of this study was to establish the most appropriate
anatomical location for harvesting of adipose tissue derived stem cells
(ASCs) with perivascular localization (pericytes) in sheep. The first
anatomical study was performed postmortem; fragments of subdermal
adipose tissue collected from different locations were processed by
standard histological methods. All subsequent interventions (n=19) were
performed intra-vitally on sedated animals. Samples of about 0.5 cm3
were harvested aseptically from the following anatomical locations:
interscapular, paravertebral - lumbar and coccygeal, groin, perimammar,
great omentum and perirenal. After harvesting, samples were placed in
cell culture medium (DMEM/10% FBS10, 2% antibiotic/antifungal) and
ASCs were isolated and cultured in vitro as described by Zuk (2001) and
Gimble (2002) for subsequent use in studies of cardiovascular tissue
regeneration. Microscopically we observed mature adipose tissue with
the presence of small blood vessels in all tissues. Harvests from the
paralombar areas did not yield ASCs. The vascular density was higher in
the perivisceral and the somatic fat. However, due to the easier surgical
approach, consistency of viable cells and to prevent postoperative
complications, the interscapular area was chosen as the preferred site
for isolation and culture of ASCs in adult sheep. Ongoing studies are
testing the in vitro pluripotency of our sheep ASCs and their in vivo
ability to sustain valve regeneration as autologous ASC-seeded valve
scaffolds.
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Decellularisation of Allogeneic Aortic and Pulmonary Valves using Low
Concentration SDS
Tayyebeh Vafaee1, Daniel Thomas1, Paul Rooney2, John N Kearney2, Helen
Berry3, Louise Jennings1, John Fisher1, Eileen Ingham1
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Over 5,000 patients benefit from heart valve replacement in the UK
annually. Cryopreserved allografts are the "gold standard" but these are
subject to immunological responses leading to calcification and stenosis
resulting in multiple reoperations. We have developed methods to
remove the immunogenic cells from porcine aortic valves whilst
preserving the biochemical and biomechanical properties (1, 2) and
shown these to regenerate in the pulmonary position in sheep (3). This
project aims to translate this technology to human cardiac valves for the
benefit of patients in the UK.
Five aortic and 3 pulmonary cryopreserved valves were treated
sequentially with: hypotonic tris buffer, 0.1% (w/v) SDS in hypotonic
buffer plus protease inhibitors and then treated with nucleases to
remove nucleic acids. The histology and DNA content of four different
regions of the acellular valves were compared to untreated
cryopreserved valves. These studies were repeated on 4 pulmonary and
4 aortic valves to determine the robustness of the process, and these
valves were also tested for biocompatibility using extract and contact
cytotoxicity assays, and analysed for collagen and glycosaminoglycan
content. H&E staining of acellular tissues showed no evidence of cell
nuclei or cell remnants. Quantitative analysis for total DNA content
showed that acellular valves had less than 15ng DNA /mg wet tissue.
There was no evidence of cytotoxicity and acellular tissue showed loss
of GAGs and retention of collagen.
Allogeneic cardiac valves successfully decellularised, whilst maintaining
their histoarchitecture. The retention of collagen and loss of GAGs was
expected based on previous studies.
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Human mesenchymal stem cells (hMSCs) have shown to release a
plethora of soluble factors that are associated with paracrine therapeutic
effects. In vascular tissue engineering, seeded cells including hMSCs
have shown to be a major factor involved in the induction of in situ
remodeling and neo-tissue formation of bioengineered constructs. In
addition, functional improvement following myocardial infarction has
been reported after injection of MSC conditoned media (CM).
Therefore the presented study aims at the in vitro comparison of
different hMSC sources as to their chemoattractic properties. hMSCs
were isolated from amniotic fluid, adipose tissue, bone marrow,
wharton's jelly and vascular tissues as control cell source. For each
source a phenotypic profile was achieved including expression of MSC
markers, multilineage differentiation and proliferation capacities. CM of
all cell sources were evaluated as to their chemoattractive potential to
induce PBMC migration in a transwell migration assay.
Transanastomotic ingrowth was examined with an in vitro endothelial
scratch assay.
The results pointed towards an increased monocyte migration in MSC
CM with significantly higher values compared to controls. The
comparative analysis showed that umbilical cord MSCs have the highest
chemoattractive capacity. No significant differences between the cell
sources were found in the endothelial scratch assay.
In conclusion, these preliminary results suggest that CM of hMSCs has a
major potential in the recruitment of monocytes in vitro, while the
attraction of endothelial cells was not enhanced. Future experiments will
aim at a profiling of the secretoma of all hMSC sources to identify
functionally relevant factors involved.
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In Vivo Investigation of Stented Monoleaflet PGA‐P4HB Based Valves in The
Arterial Circulation of a Rat Model.
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Simon Peter Hoerstrup1
1
Swiss Center for Regenerative Medicine, University Hospital of Zurich, Zurich,
Switzerland, 2Equine Department, Clinic for Equine Internal Medicine, Vetsuisse
Faculty, University of Zurich, Zurich, Switzerland
Cardiovascular tissue engineering aims at the creation of stem cellbased living autologous substitutes to overcome the limitations of
currently used cardiovascular replacement materials for cardiovascular
valve disease. Experiments in sheep, being a gold standard animal
model for in vivo preclinical cardiovascular assessment, cannot be used
to unravel underlying mechanisms of tissue formation and in situ
remodelling. Therefore the investigation of implanted tissue engineered
vascular grafts (TEVGs) in the venous/arterial circulation of rodents has
been intensively initiated as this would allow for the assessment of
constructs remodelling in immune-incompetent or transgenic strains.
Nevertheless to extrapolate findings from vessel-like structures to more
complex "dynamic" structures of valves, more hemodynamically relevant
model must be created, which was the aim of this study. For this stented
monoleaflet PGA-P4HB valves (n=5, length= 2mm, diameter=1.5mm)
were created and successfully implanted infrarenaly into abdominal
aorta of Wistar Outbreed Rats (n=5) by catheter based technique. All
animals survived the entire time of experiment and were stable during
the surgery and post-operative ultrasound evaluation. Also no significant
hemodynamic changes were observed. Nevertheless ultrasonographic
evaluation revealed only minor leaflet movement (n=2 out of 5) in arterial
circulation, most probably due to geometrical and hemodynamic
reasons. Histological evaluation revealed some infiltration (within 3
hours) both into the wall and the leaflet and no signs for thrombus
formation. These findings support the need for valve like structures
assessment in the environment more similar to orthotopic cardiac one
with more physiological flow conditions as well as structural adaptations
of the bioengineered leaflets used.
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Acellular Mitral Valve Scaffold with Intact Annulus and Chordae Tendinae for
Tissue Engineering
Cristopher deBorde1, Lee Sierad1, Sourav Patnaik2, Jun Liao2, Agneta
Simionescu1
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The worldwide prevalence of degenerative mitral valve pathologies
coupled with reparative and replacement strategies would beneficiate
from improved solutions offered by tissue engineering strategies
employing biological scaffolds and stem cells. In order to develop mitral
valve scaffolds with optimal mechanical and biological properties,
porcine fresh mitral valves were subjected to the removal of all cellular
components, while leaving the extracellular matrix components intact.
These acellular scaffolds were treated with penta-galloyl glucose (PGG),
a polyphenol that binds to collagen and elastin and renders the
extracellular matrix of the annulus, leaflets, and chordae tendinae
resistant to rapid enzymatic degradation. Scaffolds were also evaluated
for their mechanical properties, using biaxial tensile tests and thermal
denaturation profiles. After seeding the annulus scaffolds with human
smooth muscle cells and the leaflets with human adipose tissue derived
stem cells, the constructs were mounted in a heart valve bioreactor. Cell
proliferation and viability were evaluated after testing under static and
dynamic bioreactor conditions for three weeks. Histological and
immunohistochemical results indicated that there was complete removal
of cellular components including DNA and cell proteins, yet a clear
retention of both collagen and elastin. PGG treatment stabilized the
extracellular matrix components of the scaffolds, improving the
resistance to proteases and the mechanical properties of the leaflets and
annulus. Cells were successfully injected within the scaffold and were
maintained alive in vitro. Overall, we have developed a cytocompatible
mitral valve scaffold, with adequate mechanical properties.
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Whole Aortic Root Decellularization and Recellularization: An Elusive Task in
Heart Valve Tissue Engineering
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The long-term goal of this project is to generate living, tissue-engineered
(TE) heart valves from biological scaffolds and autologous stem cells. At
the basic level, a successful TE device must withstand mechanical
stresses immediately upon implantation without posing risks of
immunological rejection. The three main challenges to this objective are
complete decellularization of porcine aortic valve roots (AVR) including
the aortic root wall and sinus, efficacious seeding of adult stem cells
within cusps, and the controlled dynamic progressive conditioning before
implantation. We hypothesized that these challenges will not likely be
overcome without using advanced bioreactor systems. We developed
integrated platform technologies for complete AVR decellularization and
cell seeding. Porcine AVRs were mounted into universal “no-touch”
tissue-holding devices, treated with detergents and enzymes in a
pulsatile perfusion system, and analyzed by histology and DNA
quantitation. Human adipose-tissue derived stem cells (hASCs) were
injected into cusps prior to surface recellularization in seeding chambers.
The AVRs were progressively conditioned in heart valve bioreactors until
reaching pulmonary conditions. Cell retention was assessed through
surface imaging and histology. Decellularization of the entire porcine
AVR (especially the aortic wall) was not possible through immersion
techniques, but was successful using our pulsatile perfusion system.
Utilizing the rotating seeding chambers resulted in more complete
seeding as compared to dropwise seeding methods. Progressive
conditioning regimens facilitated good initial cellular retention and stem
cell pre-differentiation into cells resembling valvular interstitial cells.
Overall, we have developed the basic equipment and expertise
necessary to the successful development of TE cardiovascular products.
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An increasing number of young patients are choosing bioprostheses for
aortic valve replacement, but Ross operation deserves consideration as
an alternative biological substitute. Reoperation rates after the Ross
procedure and after bioprosthetic AVR, however remain a concern in
these patients.
We report reasons of reoperation after the Ross procedure for different
age groups.
Reoperation rates of 1.925 patients (mean age 41.2±15.3 years, 1.444
male) with a mean follow-up of 7.4±4.7 years (range 0.00 - 18.51 years,
12866.6 patient years) were analyzed in three age groups (Group I < 40
years, Group II 40-60 years, Group III > 60 years). Reasons of
reoperation were figured out.
In Group I 12% (after 4.6±4.2 years), in Group II 6% (after 5.12±4.65
years) and in Group III 9% after (5.0±4.8 years) of the patients had to be
reoperated. Mean interval to reoperation in bioprostheses was about 8
years in younger and about 13 years in middle aged patients. Mots
frequent reasons of reoperation were in: Group I SVD of the homograft
(7%), Group II NSVD of the autograft (3%) and Group III SVD of the
autograft (6.5%).
There is some evidence that in younger patients the reason of
reoperation after Ross procedure is mainly SVD of the homograft and if
there is a need for reoperation it is probably earlier than in patients with
bioprostheses.
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